US11696959B2 - Nanoparticle-cell construct with platinum anti-cancer agent - Google Patents

Nanoparticle-cell construct with platinum anti-cancer agent Download PDF

Info

Publication number
US11696959B2
US11696959B2 US16/066,628 US201616066628A US11696959B2 US 11696959 B2 US11696959 B2 US 11696959B2 US 201616066628 A US201616066628 A US 201616066628A US 11696959 B2 US11696959 B2 US 11696959B2
Authority
US
United States
Prior art keywords
nanoparticle
substituted
cancer
unsubstituted
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active, expires
Application number
US16/066,628
Other languages
English (en)
Other versions
US20190022246A1 (en
Inventor
Pengpeng CAO
Jacob Berlin
Karen Aboody
Rachael MOONEY
Wafa ABIDI
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
City of Hope
Original Assignee
City of Hope
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by City of Hope filed Critical City of Hope
Priority to US16/066,628 priority Critical patent/US11696959B2/en
Publication of US20190022246A1 publication Critical patent/US20190022246A1/en
Assigned to CITY OF HOPE reassignment CITY OF HOPE ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: ABIDI, Wafa
Assigned to CITY OF HOPE reassignment CITY OF HOPE ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: MOONEY, Rachael, ABOODY, KAREN, BERLIN, JACOB, CAO, Pengpeng
Application granted granted Critical
Publication of US11696959B2 publication Critical patent/US11696959B2/en
Active legal-status Critical Current
Adjusted expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6923—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being an inorganic particle, e.g. ceramic particles, silica particles, ferrite or synsorb
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6901—Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/242—Gold; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/244—Lanthanides; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Definitions

  • Nanomedicines One goal of nanomedicine is to design and synthesize drug delivery vehicles that can carry sufficient drug loads, efficiently cross physiological barriers to reach target sites, and safely and sustainably treat diseases.
  • Organic nanomedicines including liposomes, drug-polymer conjugates, dendrimers, polymeric micelles and nanoparticles (NPs), have been studied as potential drug delivery systems.
  • Each delivery platform has its advantages. For example, high drug loadings have been achieved in liposomes, but the intrinsic structural stability of liposomes is undesirably low, especially under fluid shear stress during circulation.
  • Silica NPs used for biomedical applications can be categorized as mesoporous or nonporous (solid) NPs, both of which bearing amorphous silica structure.
  • Mesoporous silica NPs characterized by mesopores (2-50 nm pore size) are widely used for delivery of active payloads based on physical or chemical adsorption.
  • nonporous silica NPs often deliver cargo through encapsulation or conjugation.
  • NSCs Neural Stem Cells
  • NSCs have demonstrated inherent tumor tropic properties (e.g. to ovarian cancer cells) in vitro and in vivo following intraperitoneal administration.
  • NSCs generally do not intrinsically have anti-tumor efficacy.
  • a silica nanoparticle including a platinum anti-cancer agent, wherein the platinum anti-cancer agent is conjugated to silica directly, though an oxygen linker, or through a nitrogen linker.
  • a cell including a nanoparticle described herein.
  • the cell is a tumor tropic cell, macrophage, stem cell (e.g., neural or mesenchymal), or T-cell.
  • a nanoparticle-cell construct including an inorganic nanoparticle covalently attached to a protein through a covalent linker, the covalent linker having the formula: (Ia) -L 2 -X 1 -L 1 -X 2 -L 3 - or (Ib) -L 2 -X 2 -L 3 -; wherein X 1 and X 2 are independently a bioconjugate linker or a bond, wherein at least one of X 1 or X 2 is a bioconjugate linker; L 1 is independently a polymeric linker; L 2 is independently a bond, —NR 1a , —O—, —S—, —C(O)—, —C(O)O—, —S(O)—, —S(O) 2 —, —NR 1a C(O)—, —C(O)NR 1b —, —C(O)(CH 2 ) z1 —, —NR 1a
  • a pharmaceutical composition including a pharmaceutically acceptable excipient and a nanoparticle, cell, or nanoparticle-cell construct, each as described herein or a pharmaceutically acceptable salt thereof.
  • a method of treating cancer in a subject in need of such treatment including administering to the subject in need thereof a therapeutically effective amount of the nanoparticle, the cell, or the nanoparticle-cell construct, each as described herein.
  • FIG. 1 A TEM image of cisplatin loaded nanoparticles at different loading levels. Comparing to the control nanoparticles SiNP-empty (i.e. without a drug added), SiNP-Cis particles loaded with 3 mg, 6 mg, and 12 mg cisplatin also maintained their morphology. They appear to be roughly the same size and shape as the control NPs. The nanoparticles are monodisperse and colloidally stable in water.
  • FIG. 2 A TEM image of carboplatin loaded nanoparticles.
  • the synthesis of SiNP-Carbo was identical to standard synthetic preparation of SiNP-Cis. Instead of 12 mg cisplatin, 12 mg of carboplatin was added to the reaction mixture. Comparing to SiNP-Cis particles, SiNP-Carbo also maintained their morphology. They appear to be roughly the same size and shape to SiNP-Cis.
  • FIG. 3 High resolution TEM image of empty and cisplatin loaded nanoparticles. Dark spots indicating Pt are only visible in the loaded particles.
  • FIG. 4 XPS analysis of cisplatin loaded nanoparticles.
  • FIG. 5 The effects of surface modification. PEGylated SiNP-Cis retained their morphology as they had very similar shape and size to SiNP-Cis. The amount of Pt in SiNP-Cis-PEG was measured by ICP-MS, noted to be about 0.1 ⁇ g/ ⁇ L Pt.
  • FIGS. 6 A- 6 C The results of the delayed release for SiNP-Cis synthesized using 200 ⁇ L TEOS and 500 ⁇ L NH 4 OH.
  • SiNP-Cis was able to delay the effect of cisplatin on NSCs by roughly 2 d. This may be enough time for NSCs loaded with SiNP-Cis to migrate to tumors.
  • FIGS. 7 A- 7 D The effect of treatment of NSCs ( FIGS. 7 A- 7 B ) and OVCAR8 ( FIGS. 7 C- 7 D ) cells with SiNP-Cis made using two different synthesis protocols, 200 ⁇ L TEOS and 500 ⁇ L NH 4 OH ( FIG. 7 B and FIG. 7 D ) vs 1000 ⁇ L TEOS and 300 ⁇ L NH 4 OH ( FIG. 7 A and FIG. 7 C ).
  • FIG. 8 The loading of NSCs with SiNP-Cis. The cells maintained their tumor tropism after loading.
  • FIGS. 9 A- 9 D The effects of loaded NSCs on OVCAR 8 cells.
  • the cells were cocultured and the amount of OVCAR8 cells was measured by luciferase imaging.
  • Cells loaded with SiNP-Cis made using 1000 ⁇ L TEOS and 300 ⁇ L NH 4 OH showed good OVCAR8 killing when a DNA-repair inhibitor (VE-822) was added ( FIGS. 9 A and 9 C ) but not in the absence ( FIGS. 9 B and 9 D ), while SiNP-Cis made using 200 ⁇ L TEOS and 500 ⁇ L NH 4 OH ( FIGS. 9 C- 9 D ) did not show good killing in either condition.
  • VE-822 DNA-repair inhibitor
  • FIG. 10 Results of Pt accumulated at tumors in animal studies. At every time point, tumors from animals injected with NSC+SiNP-Cis showed enhanced accumulation and retention of Pt.
  • FIGS. 11 A- 11 D Results of total platinum accumulation at the organs, stomach, lung, mesentry, spleen, liver, and kidney, respectively.
  • FIG. 12 Results of the total amount of Pt accumulated at tumors after 24 hrs, the combined result of 2 animal studies.
  • FIGS. 13 A- 13 C The experimental synthesis scheme showing the bare silica nanoparticle (SiNP—OH) and how it can be functionalized with functional groups, or with polymers such as polyethylene glycol, or a combination of polyethylene glycol with functional groups. Tables show the ratios of polymers/functional groups tested, including preferred ratios of non-functional PEG:functionalized PEG.
  • FIG. 14 Cell labeling results determining the preferred ratio of non-functional PEG:functionalized PEG.
  • FIG. 14 shows 80:20 non-functional PEG:functionalized PEG.
  • NSCs were labeled with PEGylated SiNPs at both 4° C. and 37° C. for 30 min in FIG. 14 .
  • the amount of Mal-PEG on the NP surface was too low and NSCs were not sufficiently labeled with SiNPs.
  • FIG. 15 Cell labeling results determining the preferred ratio of non-functional PEG:functionalized PEG.
  • FIG. 15 shows 50:50 non-functional PEG:functionalized PEG. NSCs were labeled with PEGylated SiNPs at 37° C. for 30 min in FIG. 15 . At the composition of 50%:50%, NSCs were labeled with much more NP-PEG11-3400. It appears that the shorter functional Mal-PEG3400 works better than the Mal-PEG5000. To ensure the reactivity between maleimide-thiol covalent bond formation, all future cell labeling steps were done at 37° C.
  • FIG. 16 Further optimizations of cell labeling studies. It appears that labeling NSCs via functionalized PEGylated SiNPs reaches a limit. NP attachment to the cell surface will eventually plateau as more NPs conjugate to cells. At 50%:50% composition, there was not much difference in the size of functional Mal-PEGs while making functional SiNPs. Mal-PEG2000 and Mal-PEG3400 appear to work better than Mal-PEG5000. At 80%:20%, Mal-PEG2000 is preferred over Mal-PEG3400 and Mal-PEG5000 as it was able to label NSCs efficiently.
  • FIGS. 17 A- 17 D Confocal images of NSCs labeled with functional PEG-SiNPs.
  • SiNP—OH those functionalized with surface amines
  • SiNP—Mal those further derivatized with surface maleimides
  • SiNP-Mal-PEG-backfill For PEGylated SiNPs, little association with the cells was seen.
  • SiNP-Mal-PEG-backfill For PEGylated SiNPs, little association with the cells was seen.
  • SiNPs also functionalized with functional groups, SiNPs were associated with the cells but were not found in the perinuclear space, indicating there were most
  • FIGS. 18 A- 18 B Confocal images and 3D reconstruction of NSCs labeled with functional PEG-SiNPs after 24 hours, specifically NSC+SiNP-Mal.
  • FIGS. 19 A- 19 C Confocal images and 3D reconstruction of NSCs labeled with functional PEG-SiNPs after 24 hours, specifically NSC+SiNP-(PEG 11 ) 3 -20% Mal.
  • FIG. 20 Cell labeling with bare and PEGylated silica nanoparticles. Comparing the PEGs, PEG 1000 vs. PEG 2000 , (PEG 11 ) 3 vs. (PEG 24 ) 3 , it appears that shorter PEGs perform better at reducing the non-specific binding of SiNPs to cells as cells had lower level of red fluorescence. Comparing the structure of the PEGs, linear vs. branched, branched PEGs, (PEG 11 ) 3 and (PEG 24 ) 3 work better than the linear PEGs, PEG 1000 and PEG 2000 . Overall, (PEG 11 ) 3 is preferred at preventing non-specific binding of the SiNPs to NSCs.
  • FIG. 21 Cell labeling to identify the non-specific binding of bare silica nanoparticles and PEG-silica nanoparticles to neural stem cells.
  • NSCs treated with bare SiNPs have very high level of red fluorescence, indicating high level of non-specific binding and/or internalization of bare SiNPs to the cells.
  • NSCs treated with PEGylated SiNPs have reduced non-specific binding and/or internalization of SiNPs to the cells.
  • NPs nanoparticles
  • chemotherapeutic agents e.g., platinum anti-cancer agents
  • delayed-drug release NP/NSC constructs are provided to realize a modular and general drug targeting system for ovarian cancer.
  • unmodified cisplatin molecules are encapsulated by silica NPs via a one-pot reaction, and these cisplatin-NPs demonstrated delayed drug release over 3 days via in vitro efficacy MTT assay.
  • NSCs may be labeled with cisplatin-NPs and the resulting NSC-NP constructs injected in mice bearing ovarian cancer tumors. The amount of Pt accumulation may be quantified at tumors and in organs by ICP-MS. Our data demonstrated that NSC-NP constructs have much superior accumulation and retention of Pt in tumors than both free cisplatin and free cisplatin-NPs.
  • substituent groups are specified by their conventional chemical formulae, written from left to right, they equally encompass the chemically identical substituents that would result from writing the structure from right to left, e.g., —CH 2 O— is equivalent to —OCH 2 —.
  • alkyl by itself or as part of another substituent, means, unless otherwise stated, a straight (i.e., unbranched) or branched non-cyclic carbon chain (or carbon), or combination thereof, which may be fully saturated, mono- or polyunsaturated and can include di- and multivalent radicals, having the number of carbon atoms designated (i.e., C 1 -C 10 means one to ten carbons).
  • saturated hydrocarbon radicals include, but are not limited to, groups such as methyl, ethyl, n-propyl, isopropyl, n-butyl, t-butyl, isobutyl, sec-butyl, (cyclohexyl)methyl, homologs and isomers of, for example, n-pentyl, n-hexyl, n-heptyl, n-octyl, and the like.
  • An unsaturated alkyl group is one having one or more double bonds or triple bonds.
  • Examples of unsaturated alkyl groups include, but are not limited to, vinyl, 2-propenyl, crotyl, 2-isopentenyl, 2-(butadienyl), 2,4-pentadienyl, 3-(1,4-pentadienyl), ethynyl, 1- and 3-propynyl, 3-butynyl, and the higher homologs and isomers.
  • An alkoxy is an alkyl attached to the remainder of the molecule via an oxygen linker (—O—).
  • An alkyl moiety may be an alkenyl moiety.
  • An alkyl moiety may be an alkynyl moiety.
  • An alkyl moiety may be fully saturated.
  • An alkenyl may include more than one double bond and/or one or more triple bonds in addition to the one or more double bonds.
  • An alkynyl may include more than one triple bond and/or one or more double bonds in addition to the one or more triple bonds.
  • alkylene by itself or as part of another substituent, means, unless otherwise stated, a divalent radical derived from an alkyl, as exemplified, but not limited by, —CH 2 CH 2 CH 2 CH 2 —.
  • an alkyl (or alkylene) group will have from 1 to 24 carbon atoms, with those groups having 10 or fewer carbon atoms being preferred in the present invention.
  • a “lower alkyl” or “lower alkylene” is a shorter chain alkyl or alkylene group, generally having eight or fewer carbon atoms.
  • alkenylene by itself or as part of another substituent, means, unless otherwise stated, a divalent radical derived from an alkene.
  • heteroalkyl by itself or in combination with another term, means, unless otherwise stated, a stable straight or branched non-cyclic chain, or combinations thereof, including at least one carbon atom and at least one heteroatom (e.g. O, N, P, Si, and S), and wherein the nitrogen and sulfur atoms may optionally be oxidized, and the nitrogen heteroatom may optionally be quaternized.
  • the heteroatom(s) e.g. O, N, P, S, and Si
  • Examples include, but are not limited to: —CH 2 —CH 2 —O—CH 3 , —CH 2 —CH 2 —NH—CH 3 , —CH 2 —CH 2 —N(CH 3 )—CH 3 , —CH 2 —S—CH 2 —CH 3 , —CH 2 —CH 2 , —S(O)—CH 3 , —CH 2 —CH 2 —S(O) 2 —CH 3 , —CH ⁇ CH—O—CH 3 , —Si(CH 3 ) 3 , —CH 2 —CH ⁇ N—OCH 3 , —CH ⁇ CH—N(CH 3 )—CH 3 , —O—CH 3 , —O—CH 2 —CH 3 , and —CN.
  • a heteroalkyl moiety may include one heteroatom (e.g., O, N, S, Si, or P).
  • a heteroalkyl moiety may include two optionally different heteroatoms (e.g., O, N, S, Si, or P).
  • a heteroalkyl moiety may include three optionally different heteroatoms (e.g., O, N, S, Si, or P).
  • a heteroalkyl moiety may include four optionally different heteroatoms (e.g., O, N, S, Si, or P).
  • a heteroalkyl moiety may include five optionally different heteroatoms (e.g., O, N, S, Si, or P).
  • a heteroalkyl moiety may include up to 8 optionally different heteroatoms (e.g., O, N, S, Si, or P).
  • the term “heteroalkenyl,” by itself or in combination with another term, means, unless otherwise stated, a heteroalkyl including at least one double bond.
  • a heteroalkenyl may optionally include more than one double bond and/or one or more triple bonds in additional to the one or more double bonds.
  • the term “heteroalkynyl,” by itself or in combination with another term means, unless otherwise stated, a heteroalkyl including at least one triple bond.
  • a heteroalkynyl may optionally include more than one triple bond and/or one or more double bonds in additional to the one or more triple bonds.
  • heteroalkylene by itself or as part of another substituent, means, unless otherwise stated, a divalent radical derived from heteroalkyl, as exemplified, but not limited by, —CH 2 —CH 2 —S—CH 2 —CH 2 — and —CH 2 —S—CH 2 —CH 2 —NH—CH 2 —.
  • heteroatoms can also occupy either or both of the chain termini (e.g., alkyleneoxy, alkylenedioxy, alkyleneamino, alkylenediamino, and the like).
  • heteroalkyl groups include those groups that are attached to the remainder of the molecule through a heteroatom, such as —C(O)R′, —C(O)NR′, —NR′R′′, —OR′, —SR′, and/or —SO 2 R′.
  • heteroalkyl is recited, followed by recitations of specific heteroalkyl groups, such as —NR′R′′ or the like, it will be understood that the terms heteroalkyl and —NR′R′′ are not redundant or mutually exclusive. Rather, the specific heteroalkyl groups are recited to add clarity. Thus, the term “heteroalkyl” should not be interpreted herein as excluding specific heteroalkyl groups, such as —NR′R′′ or the like.
  • cycloalkyl and heterocycloalkyl by themselves or in combination with other terms, mean, unless otherwise stated, non-aromatic cyclic versions of “alkyl” and “heteroalkyl,” respectively, wherein the carbons making up the ring or rings do not necessarily need to be bonded to a hydrogen due to all carbon valencies participating in bonds with non-hydrogen atoms. Additionally, for heterocycloalkyl, a heteroatom can occupy the position at which the heterocycle is attached to the remainder of the molecule.
  • cycloalkyl examples include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, 1-cyclohexenyl, 3-cyclohexenyl, cycloheptyl, 3-hydroxy-cyclobut-3-enyl-1,2, dione, 1H-1,2,4-triazolyl-5(4H)-one, 4H-1,2,4-triazolyl, and the like.
  • heterocycloalkyl examples include, but are not limited to, 1-(1,2,5,6-tetrahydropyridyl), 1-piperidinyl, 2-piperidinyl, 3-piperidinyl, 4-morpholinyl, 3-morpholinyl, tetrahydrofuran-2-yl, tetrahydrofuran-3-yl, tetrahydrothien-2-yl, tetrahydrothien-3-yl, 1-piperazinyl, 2-piperazinyl, and the like.
  • a heterocycloalkyl moiety may include one ring heteroatom (e.g., O, N, S, Si, or P).
  • a heterocycloalkyl moiety may include two optionally different ring heteroatoms (e.g., O, N, S, Si, or P).
  • a heterocycloalkyl moiety may include three optionally different ring heteroatoms (e.g., O, N, S, Si, or P).
  • a heterocycloalkyl moiety may include four optionally different ring heteroatoms (e.g., O, N, S, Si, or P).
  • a heterocycloalkyl moiety may include five optionally different ring heteroatoms (e.g., O, N, S, Si, or P).
  • a heterocycloalkyl moiety may include up to 8 optionally different ring heteroatoms (e.g., O, N, S, Si, or P).
  • halo or “halogen,” by themselves or as part of another substituent, mean, unless otherwise stated, a fluorine, chlorine, bromine, or iodine atom. Additionally, terms such as “haloalkyl” are meant to include monohaloalkyl and polyhaloalkyl.
  • halo(C 1 -C 4 )alkyl includes, but is not limited to, fluoromethyl, difluoromethyl, trifluoromethyl, 2,2,2-trifluoroethyl, 4-chlorobutyl, 3-bromopropyl, and the like.
  • acyl means, unless otherwise stated, —C(O)R where R is a substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl.
  • aryl means, unless otherwise stated, a polyunsaturated, aromatic, hydrocarbon substituent, which can be a single ring or multiple rings (preferably from 1 to 3 rings) that are fused together (i.e., a fused ring aryl) or linked covalently.
  • a fused ring aryl refers to multiple rings fused together wherein at least one of the fused rings is an aryl ring.
  • heteroaryl refers to aryl groups (or rings) that contain at least one heteroatom such as N, O, or S, wherein the nitrogen and sulfur atoms are optionally oxidized, and the nitrogen atom(s) are optionally quaternized.
  • heteroaryl includes fused ring heteroaryl groups (i.e., multiple rings fused together wherein at least one of the fused rings is a heteroaromatic ring).
  • a 5,6-fused ring heteroarylene refers to two rings fused together, wherein one ring has 5 members and the other ring has 6 members, and wherein at least one ring is a heteroaryl ring.
  • a 6,6-fused ring heteroarylene refers to two rings fused together, wherein one ring has 6 members and the other ring has 6 members, and wherein at least one ring is a heteroaryl ring.
  • a 6,5-fused ring heteroarylene refers to two rings fused together, wherein one ring has 6 members and the other ring has 5 members, and wherein at least one ring is a heteroaryl ring.
  • a heteroaryl group can be attached to the remainder of the molecule through a carbon or heteroatom.
  • Non-limiting examples of aryl and heteroaryl groups include phenyl, 1-naphthyl, 2-naphthyl, 4-biphenyl, 1-pyrrolyl, 2-pyrrolyl, 3-pyrrolyl, 3-pyrazolyl, 2-imidazolyl, 4-imidazolyl, pyrazinyl, 2-oxazolyl, 4-oxazolyl, 2-phenyl-4-oxazolyl, 5-oxazolyl, 3-isoxazolyl, 4-isoxazolyl, 5-isoxazolyl, 2-thiazolyl, 4-thiazolyl, 5-thiazolyl, 2-furyl, 3-furyl, 2-thienyl, 3-thienyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, 2-pyrimidyl, 4-pyrimidyl, 5-benzothiazolyl, purinyl, 2-benzimidazolyl, 5-indolyl, 1-isoquinoly
  • arylene and heteroarylene are selected from the group of acceptable substituents described below.
  • Non-limiting examples of aryl and heteroaryl groups include pyridinyl, pyrimidinyl, thiophenyl, thienyl, furanyl, indolyl, benzoxadiazolyl, benzodioxolyl, benzodioxanyl, thianaphthanyl, pyrrolopyridinyl, indazolyl, quinolinyl, quinoxalinyl, pyridopyrazinyl, quinazolinonyl, benzoisoxazolyl, imidazopyridinyl, benzofuranyl, benzothienyl, benzothiophenyl, phenyl, naphthyl, biphenyl, pyrrolyl, pyrazolyl, imidazolyl, pyrazinyl, oxazolyl, isoxazolyl, thiazolyl, furylthienyl, pyridyl, pyrimid
  • a heteroaryl moiety may include one ring heteroatom (e.g., O, N, or S).
  • a heteroaryl moiety may include two optionally different ring heteroatoms (e.g., O, N, or S).
  • a heteroaryl moiety may include three optionally different ring heteroatoms (e.g., O, N, or S).
  • a heteroaryl moiety may include four optionally different ring heteroatoms (e.g., O, N, or S).
  • a heteroaryl moiety may include five optionally different ring heteroatoms (e.g., O, N, or S).
  • An aryl moiety may have a single ring.
  • An aryl moiety may have two optionally different rings.
  • An aryl moiety may have three optionally different rings.
  • An aryl moiety may have four optionally different rings.
  • a heteroaryl moiety may have one ring.
  • a heteroaryl moiety may have two optionally different rings.
  • a heteroaryl moiety may have three optionally different rings.
  • a heteroaryl moiety may have four optionally different rings.
  • a heteroaryl moiety may have five optionally different rings.
  • a fused ring heterocyloalkyl-aryl is an aryl fused to a heterocycloalkyl.
  • a fused ring heterocycloalkyl-heteroaryl is a heteroaryl fused to a heterocycloalkyl.
  • a fused ring heterocycloalkyl-cycloalkyl is a heterocycloalkyl fused to a cycloalkyl.
  • a fused ring heterocycloalkyl-heterocycloalkyl is a heterocycloalkyl fused to another heterocycloalkyl.
  • Fused ring heterocycloalkyl-aryl, fused ring heterocycloalkyl-heteroaryl, fused ring heterocycloalkyl-cycloalkyl, or fused ring heterocycloalkyl-heterocycloalkyl may each independently be unsubstituted or substituted with one or more of the substitutents described herein.
  • oxo means an oxygen that is double bonded to a carbon atom.
  • alkylsulfonyl means a moiety having the formula —S(O 2 )—R′, where R′ is a substituted or unsubstituted alkyl group as defined above. R′ may have a specified number of carbons (e.g., “C 1 -C 4 alkylsulfonyl”).
  • alkyl e.g., “alkyl”, “heteroalkyl”, “cycloalkyl”, “heterocycloalkyl”, “aryl”, and “heteroaryl”
  • alkyl e.g., “alkyl”, “heteroalkyl”, “cycloalkyl”, “heterocycloalkyl”, “aryl”, and “heteroaryl”
  • Preferred substituents for each type of radical are provided below.
  • Substituents for the alkyl and heteroalkyl radicals can be one or more of a variety of groups selected from, but not limited to, —OR′, ⁇ O, ⁇ NR′, ⁇ N—OR′, —NR′R′′, —SR′, -halogen, —SiR′R′′R′′′, —OC(O)R′, —C(O)R′, —CO 2 R′, —CONR′R′′, —OC(O)NR′R′′, —NR′′C(O)R′, —NR′—C(O)NR′′R′′′, —NR′′C(O) 2 R′, —NR—C(NR′R′′R′′′) ⁇ NR′′ ′′,
  • R, R′, R′′, R′′′, and R′′′′ each preferably independently refer to hydrogen, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl (e.g., aryl substituted with 1-3 halogens), substituted or unsubstituted heteroaryl, substituted or unsubstituted alkyl, alkoxy, or thioalkoxy groups, or arylalkyl groups.
  • aryl e.g., aryl substituted with 1-3 halogens
  • substituted or unsubstituted heteroaryl substituted or unsubstituted alkyl, alkoxy, or thioalkoxy groups, or arylalkyl groups.
  • each of the R groups is independently selected as are each R′, R′′, R′′′, and R′′′′ group when more than one of these groups is present.
  • R′ and R′′ are attached to the same nitrogen atom, they can be combined with the nitrogen atom to form a 4-, 5-, 6-, or 7-membered ring.
  • —NR′R′′ includes, but is not limited to, 1-pyrrolidinyl and 4-morpholinyl.
  • alkyl is meant to include groups including carbon atoms bound to groups other than hydrogen groups, such as haloalkyl (e.g., —CF 3 and —CH 2 CF 3 ) and acyl (e.g., —C(O)CH 3 , —C(O)CF 3 , —C(O)CH 2 OCH 3 , and the like).
  • haloalkyl e.g., —CF 3 and —CH 2 CF 3
  • acyl e.g., —C(O)CH 3 , —C(O)CF 3 , —C(O)CH 2 OCH 3 , and the like.
  • substituents for the aryl and heteroaryl groups are varied and are selected from, for example: —OR′, —NR′R′′, —SR′, -halogen, —SiR′R′′R′′′, —OC(O)R′, —C(O)R′, —CO 2 R′, —CONR′R′′, —OC(O)NR′R′′, —NR′′C(O)R′, —NR′—C(O)NR′′R′′′, —NR′′C(O) 2 R′, —NR—C(NR′R′′R′′′) ⁇ NR′′′′, —NR—C(NR′ R′′) ⁇ NR′′′, —S(O)R′, —S(O) 2 R′, —S(O) 2 NR′R′′, —NRSO 2 R′, —NR′NR′′R′′′, —ONR′R′′, —NR′C ⁇ (O)
  • Two or more substituents may optionally be joined to form aryl, heteroaryl, cycloalkyl, or heterocycloalkyl groups.
  • Such so-called ring-forming substituents are typically, though not necessarily, found attached to a cyclic base structure.
  • the ring-forming substituents are attached to adjacent members of the base structure.
  • two ring-forming substituents attached to adjacent members of a cyclic base structure create a fused ring structure.
  • the ring-forming substituents are attached to a single member of the base structure.
  • two ring-forming substituents attached to a single member of a cyclic base structure create a spirocyclic structure.
  • the ring-forming substituents are attached to non-adjacent members of the base structure.
  • Two of the substituents on adjacent atoms of the aryl or heteroaryl ring may optionally form a ring of the formula -T-C(O)—(CRR′) q —U—, wherein T and U are independently —NR—, —O—, —CRR′—, or a single bond, and q is an integer of from 0 to 3.
  • two of the substituents on adjacent atoms of the aryl or heteroaryl ring may optionally be replaced with a substituent of the formula -A-(CH 2 ) r —B—, wherein A and B are independently —CRR′—, —O—, —NR—, —S—, —S(O)—, —S(O) 2 —, —S(O) 2 NR′—, or a single bond, and r is an integer of from 1 to 4.
  • One of the single bonds of the new ring so formed may optionally be replaced with a double bond.
  • two of the substituents on adjacent atoms of the aryl or heteroaryl ring may optionally be replaced with a substituent of the formula —(CRR′) s —X′— (C′′R′′R′′′) d —, where s and d are independently integers of from 0 to 3, and X′ is —O—, —NR′—, —S—, —S(O)—, —S(O) 2 —, or —S(O) 2 NR′—.
  • R, R′, R′′, and R′′′ are preferably independently selected from hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, and substituted or unsubstituted heteroaryl.
  • heteroatom or “ring heteroatom” are meant to include, oxygen (O), nitrogen (N), sulfur (S), phosphorus (P), and silicon (Si).
  • a “substituent group,” as used herein, means a group selected from the following moieties:
  • a “size-limited substituent” or “size-limited substituent group,” as used herein, means a group selected from all of the substituents described above for a “substituent group,” wherein each substituted or unsubstituted alkyl is a substituted or unsubstituted C 1 -C 20 alkyl, each substituted or unsubstituted heteroalkyl is a substituted or unsubstituted 2 to 20 membered heteroalkyl, each substituted or unsubstituted cycloalkyl is a substituted or unsubstituted C 3 -C 8 cycloalkyl, each substituted or unsubstituted heterocycloalkyl is a substituted or unsubstituted 3 to 8 membered heterocycloalkyl, each substituted or unsubstituted aryl is a substituted or unsubstituted C 6 -C 10 aryl, and each substituted or unsubstituted heteroaryl is
  • a “lower substituent” or “lower substituent group,” as used herein, means a group selected from all of the substituents described above for a “substituent group,” wherein each substituted or unsubstituted alkyl is a substituted or unsubstituted C 1 -C 8 alkyl, each substituted or unsubstituted heteroalkyl is a substituted or unsubstituted 2 to 8 membered heteroalkyl, each substituted or unsubstituted cycloalkyl is a substituted or unsubstituted C 3 -C 7 cycloalkyl, each substituted or unsubstituted heterocycloalkyl is a substituted or unsubstituted 3 to 7 membered heterocycloalkyl, each substituted or unsubstituted aryl is a substituted or unsubstituted C 6 -C 10 aryl, and each substituted or unsubstituted heteroaryl is a substitute
  • each substituted group described in the compounds herein is substituted with at least one substituent group. More specifically, in some embodiments, each substituted alkyl, substituted heteroalkyl, substituted cycloalkyl, substituted heterocycloalkyl, substituted aryl, substituted heteroaryl, substituted alkylene, substituted heteroalkylene, substituted cycloalkylene, substituted heterocycloalkylene, substituted arylene, and/or substituted heteroarylene described in the compounds herein are substituted with at least one substituent group. In other embodiments, at least one or all of these groups are substituted with at least one size-limited substituent group. In other embodiments, at least one or all of these groups are substituted with at least one lower substituent group.
  • each substituted or unsubstituted alkyl may be a substituted or unsubstituted C 1 -C 20 alkyl
  • each substituted or unsubstituted heteroalkyl is a substituted or unsubstituted 2 to 20 membered heteroalkyl
  • each substituted or unsubstituted cycloalkyl is a substituted or unsubstituted C 3 -C 8 cycloalkyl
  • each substituted or unsubstituted heterocycloalkyl is a substituted or unsubstituted 3 to 8 membered heterocycloalkyl
  • each substituted or unsubstituted aryl is a substituted or unsubstituted C 6 -C 10 aryl
  • each substituted or unsubstituted heteroaryl is a substituted or unsubstituted 5 to 10 membered heteroaryl.
  • each substituted or unsubstituted alkylene is a substituted or unsubstituted C 1 -C 20 alkylene
  • each substituted or unsubstituted heteroalkylene is a substituted or unsubstituted 2 to 20 membered heteroalkylene
  • each substituted or unsubstituted cycloalkylene is a substituted or unsubstituted C 3 -C 8 cycloalkylene
  • each substituted or unsubstituted heterocycloalkylene is a substituted or unsubstituted 3 to 8 membered heterocycloalkylene
  • each substituted or unsubstituted arylene is a substituted or unsubstituted C 6 -C 10 arylene
  • each substituted or unsubstituted heteroarylene is a substituted or unsubstituted 5 to 10 membered heteroarylene.
  • each substituted or unsubstituted alkyl is a substituted or unsubstituted C 1 -C 8 alkyl
  • each substituted or unsubstituted heteroalkyl is a substituted or unsubstituted 2 to 8 membered heteroalkyl
  • each substituted or unsubstituted cycloalkyl is a substituted or unsubstituted C 3 -C 7 cycloalkyl
  • each substituted or unsubstituted heterocycloalkyl is a substituted or unsubstituted 3 to 7 membered heterocycloalkyl
  • each substituted or unsubstituted aryl is a substituted or unsubstituted C 6 -C 10 aryl
  • each substituted or unsubstituted heteroaryl is a substituted or unsubstituted 5 to 9 membered heteroaryl.
  • each substituted or unsubstituted alkylene is a substituted or unsubstituted C 1 -C 8 alkylene
  • each substituted or unsubstituted heteroalkylene is a substituted or unsubstituted 2 to 8 membered heteroalkylene
  • each substituted or unsubstituted cycloalkylene is a substituted or unsubstituted C 3 -C 7 cycloalkylene
  • each substituted or unsubstituted heterocycloalkylene is a substituted or unsubstituted 3 to 7 membered heterocycloalkylene
  • each substituted or unsubstituted arylene is a substituted or unsubstituted C 6 -C 10 arylene
  • each substituted or unsubstituted heteroarylene is a substituted or unsubstituted 5 to 9 membered heteroarylene.
  • the compound is a chemical species set forth in the Examples section, figures, or tables
  • a substituted or unsubstituted moiety e.g., substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted alkylene, substituted or unsubstituted heteroalkylene, substituted or unsubstituted cycloalkylene, substituted or unsubstituted heterocycloalkylene, substituted or unsubstituted arylene, and/or substituted or unsubstituted heteroarylene) is unsubstituted (e.g., is an unsubstituted alkyl, unsubstituted heteroalkyl, unsubstituted cycloalkyl, unsubstituted heterocycloalkyl,
  • a substituted or unsubstituted moiety e.g., substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted alkylene, substituted or unsubstituted heteroalkylene, substituted or unsubstituted cycloalkylene, substituted or unsubstituted heterocycloalkylene, substituted or unsubstituted arylene, and/or substituted or unsubstituted heteroarylene) is substituted (e.g., is a substituted alkyl, substituted heteroalkyl, substituted cycloalkyl, substituted heterocycloalkyl, substituted aryl, substituted heteroaryl, substituted alky
  • a substituted moiety e.g., substituted alkyl, substituted heteroalkyl, substituted cycloalkyl, substituted heterocycloalkyl, substituted aryl, substituted heteroaryl, substituted alkylene, substituted heteroalkylene, substituted cycloalkylene, substituted heterocycloalkylene, substituted arylene, and/or substituted heteroarylene
  • is substituted with at least one substituent group wherein if the substituted moiety is substituted with a plurality of substituent groups, each substituent group may optionally be different. In embodiments, if the substituted moiety is substituted with a plurality of substituent groups, each substituent group is different.
  • a substituted moiety e.g., substituted alkyl, substituted heteroalkyl, substituted cycloalkyl, substituted heterocycloalkyl, substituted aryl, substituted heteroaryl, substituted alkylene, substituted heteroalkylene, substituted cycloalkylene, substituted heterocycloalkylene, substituted arylene, and/or substituted heteroarylene
  • is substituted with at least one size-limited substituent group wherein if the substituted moiety is substituted with a plurality of size-limited substituent groups, each size-limited substituent group may optionally be different. In embodiments, if the substituted moiety is substituted with a plurality of size-limited substituent groups, each size-limited substituent group is different.
  • a substituted moiety e.g., substituted alkyl, substituted heteroalkyl, substituted cycloalkyl, substituted heterocycloalkyl, substituted aryl, substituted heteroaryl, substituted alkylene, substituted heteroalkylene, substituted cycloalkylene, substituted heterocycloalkylene, substituted arylene, and/or substituted heteroarylene
  • is substituted with at least one lower substituent group wherein if the substituted moiety is substituted with a plurality of lower substituent groups, each lower substituent group may optionally be different. In embodiments, if the substituted moiety is substituted with a plurality of lower substituent groups, each lower substituent group is different.
  • a substituted moiety e.g., substituted alkyl, substituted heteroalkyl, substituted cycloalkyl, substituted heterocycloalkyl, substituted aryl, substituted heteroaryl, substituted alkylene, substituted heteroalkylene, substituted cycloalkylene, substituted heterocycloalkylene, substituted arylene, and/or substituted heteroarylene
  • the substituted moiety is substituted with a plurality of groups selected from substituent groups, size-limited substituent groups, and lower substituent groups; each substituent group, size-limited substituent group, and/or lower substituent group is different.
  • salts are meant to include salts of the active compounds that are prepared with relatively nontoxic acids or bases, depending on the particular substituents found on the compounds described herein.
  • base addition salts can be obtained by contacting the neutral form of such compounds with a sufficient amount of the desired base, either neat or in a suitable inert solvent.
  • pharmaceutically acceptable base addition salts include sodium, potassium, calcium, ammonium, organic amino, or magnesium salt, or a similar salt.
  • acid addition salts can be obtained by contacting the neutral form of such compounds with a sufficient amount of the desired acid, either neat or in a suitable inert solvent.
  • Examples of pharmaceutically acceptable acid addition salts include those derived from inorganic acids like hydrochloric, hydrobromic, nitric, carbonic, monohydrogencarbonic, phosphoric, monohydrogenphosphoric, dihydrogenphosphoric, sulfuric, monohydrogensulfuric, hydriodic, or phosphorous acids and the like, as well as the salts derived from relatively nontoxic organic acids like acetic, propionic, isobutyric, maleic, malonic, benzoic, succinic, suberic, fumaric, lactic, mandelic, phthalic, benzenesulfonic, p-tolylsulfonic, citric, tartaric, methanesulfonic, and the like.
  • inorganic acids like hydrochloric, hydrobromic, nitric, carbonic, monohydrogencarbonic, phosphoric, monohydrogenphosphoric, dihydrogenphosphoric, sulfuric, monohydrogensulfuric, hydriodic, or phosphorous acids and
  • salts of amino acids such as arginate and the like, and salts of organic acids like glucuronic or galactunoric acids and the like (see, e.g., Berge et al., Journal of Pharmaceutical Science 66:1-19 (1977)).
  • Certain specific compounds of the present invention contain both basic and acidic functionalities that allow the compounds to be converted into either base or acid addition salts.
  • Other pharmaceutically acceptable carriers known to those of skill in the art are suitable for the present invention. Salts tend to be more soluble in aqueous or other protonic solvents than are the corresponding free base forms.
  • the preparation may be a lyophilized powder in 1 mM-50 mM histidine, 0.1%-2% sucrose, 2%-7% mannitol at a pH range of 4.5 to 5.5, that is combined with buffer prior to use.
  • the compounds of the present invention may exist as salts, such as with pharmaceutically acceptable acids.
  • the present invention includes such salts.
  • examples of such salts include hydrochlorides, hydrobromides, sulfates, methanesulfonates, nitrates, maleates, acetates, citrates, fumarates, tartrates (e.g., (+)-tartrates, ( ⁇ )-tartrates, or mixtures thereof including racemic mixtures), succinates, benzoates, and salts with amino acids such as glutamic acid.
  • These salts may be prepared by methods known to those skilled in the art.
  • the neutral forms of the compounds are preferably regenerated by contacting the salt with a base or acid and isolating the parent compound in the conventional manner.
  • the parent form of the compound differs from the various salt forms in certain physical properties, such as solubility in polar solvents.
  • agents e.g. compounds, drugs, therapeutic agents
  • Prodrugs of the compounds described herein are those compounds that readily undergo chemical changes under select physiological conditions to provide the final agents (e.g. compounds, drugs, therapeutic agents). Additionally, prodrugs can be converted to agents (e.g. compounds, drugs, therapeutic agents) by chemical or biochemical methods in an ex vivo environment.
  • Prodrugs described herein include compounds that readily undergo chemical changes under select physiological conditions to provide agents (e.g. compounds, drugs, therapeutic agents) to a biological system (e.g. in a subject).
  • Certain compounds of the present invention can exist in unsolvated forms as well as solvated forms, including hydrated forms. In general, the solvated forms are equivalent to unsolvated forms and are encompassed within the scope of the present invention. Certain compounds of the present invention may exist in multiple crystalline or amorphous forms. In general, all physical forms are equivalent for the uses contemplated by the present invention and are intended to be within the scope of the present invention.
  • salt refers to acid or base salts of the compounds used in the methods of the present invention.
  • acceptable salts are mineral acid (hydrochloric acid, hydrobromic acid, phosphoric acid, and the like) salts, organic acid (acetic acid, propionic acid, glutamic acid, citric acid and the like) salts, quaternary ammonium (methyl iodide, ethyl iodide, and the like) salts.
  • Certain compounds of the present invention possess asymmetric carbon atoms (optical or chiral centers) or double bonds; the enantiomers, racemates, diastereomers, tautomers, geometric isomers, stereoisometric forms that may be defined, in terms of absolute stereochemistry, as (R)- or (S)- or, as (D)- or (L)- for amino acids, and individual isomers are encompassed within the scope of the present invention.
  • the compounds of the present invention do not include those which are known in art to be too unstable to synthesize and/or isolate.
  • the present invention is meant to include compounds in racemic and optically pure forms.
  • Optically active (R)- and (S)-, or (D)- and (L)-isomers may be prepared using chiral synthons or chiral reagents, or resolved using conventional techniques.
  • the compounds described herein contain olefinic bonds or other centers of geometric asymmetry, and unless specified otherwise, it is intended that the compounds include both E and Z geometric isomers.
  • isomers refers to compounds having the same number and kind of atoms, and hence the same molecular weight, but differing in respect to the structural arrangement or configuration of the atoms.
  • tautomer refers to one of two or more structural isomers which exist in equilibrium and which are readily converted from one isomeric form to another.
  • structures depicted herein are also meant to include all stereochemical forms of the structure; i.e., the R and S configurations for each asymmetric center. Therefore, single stereochemical isomers as well as enantiomeric and diastereomeric mixtures of the present compounds are within the scope of the invention.
  • structures depicted herein are also meant to include compounds which differ only in the presence of one or more isotopically enriched atoms.
  • compounds having the present structures except for the replacement of a hydrogen by a deuterium or tritium, or the replacement of a carbon by 13 C- or 14 C-enriched carbon are within the scope of this invention.
  • the compounds of the present invention may also contain unnatural proportions of atomic isotopes at one or more of the atoms that constitute such compounds.
  • the compounds may be radiolabeled with radioactive isotopes, such as for example tritium ( 3 H), iodine-125 ( 125 I), or carbon-14 ( 14 C). All isotopic variations of the compounds of the present invention, whether radioactive or not, are encompassed within the scope of the present invention.
  • a or “an,” as used in herein means one or more.
  • substituted with a[n] means the specified group may be substituted with one or more of any or all of the named substituents.
  • a group such as an alkyl or heteroaryl group, is “substituted with an unsubstituted C 1 -C 20 alkyl, or unsubstituted 2 to 20 membered heteroalkyl,” the group may contain one or more unsubstituted C 1 -C 20 alkyls, and/or one or more unsubstituted 2 to 20 membered heteroalkyls.
  • R substituent
  • the group may be referred to as “R-substituted.”
  • R-substituted the moiety is substituted with at least one R substituent and each R substituent is optionally different.
  • treating refers to any indicia of success in the treatment or amelioration of an injury, disease, pathology or condition, including any objective or subjective parameter such as abatement; remission; diminishing of symptoms or making the injury, pathology or condition more tolerable to the patient; slowing in the rate of degeneration or decline; making the final point of degeneration less debilitating; improving a patient's physical or mental well-being.
  • the treatment or amelioration of symptoms can be based on objective or subjective parameters; including the results of a physical examination, neuropsychiatric exams, and/or a psychiatric evaluation.
  • certain methods herein treat hyperproliferative disorders, such as cancer (e.g.
  • certain methods herein treat cancer by decreasing or reducing or preventing the occurrence, growth, metastasis, or progression of cancer or by decreasing or reducing or preventing a symptom of cancer.
  • Symptoms of cancer e.g., ovarian cancer, bladder cancer, head and neck cancer, brain cancer, breast cancer, lung cancer, cervical cancer, liver cancer, colorectal cancer, pancreatic cancer, glioblastoma, neuroblastoma, rhabdomyosarcoma, osteosarcoma, renal cancer, renal cell carcinoma, non-small cell lung cancer, uterine cancer, testicular cancer, anal cancer, bile duct cancer, biliary tract cancer, gastrointestinal carcinoid tumors, esophageal cancer, gall bladder cancer, appendix cancer, small intestine cancer, stomach (gastric) cancer, urinary bladder cancer, genitourinary tract cancer, endometrial cancer, nasopharyngeal cancer, head and neck squamous cell carcinoma, or prostate cancer
  • treating include prevention of an injury, pathology, condition, or disease (e.g. preventing the development of one or more symptoms of cancer (e.g. ovarian cancer, bladder cancer, head and neck cancer, brain cancer, breast cancer, lung cancer, cervical cancer, liver cancer, colorectal cancer, pancreatic cancer, glioblastoma, neuroblastoma, rhabdomyosarcoma, osteosarcoma, renal cancer, renal cell carcinoma, non-small cell lung cancer, uterine cancer, testicular cancer, anal cancer, bile duct cancer, biliary tract cancer, gastrointestinal carcinoid tumors, esophageal cancer, gall bladder cancer, appendix cancer, small intestine cancer, stomach (gastric) cancer, urinary bladder cancer, genitourinary tract cancer, endometrial cancer, nasopharyngeal cancer, head and neck squamous cell carcinoma, or prostate cancer).
  • cancer e.g. ovarian cancer, bladder cancer, head and neck cancer, brain
  • liver cancer e.g. hepatocellular carcinoma
  • lung cancer e.g. non-small cell lung carcinoma, squamous cell lung carcinoma, adenocarcinoma, large cell lung carcinoma, small cell lung carcinoma, carcinoid, sarcoma, cisplatin resistant lung
  • Additional examples include, cancer of the thyroid, endocrine system, brain, breast, cervix, colon, head & neck, liver, kidney, lung, non-small cell lung, melanoma, mesothelioma, ovary, sarcoma, stomach, uterus or Medulloblastoma, Hodgkin's Disease, Non-Hodgkin's Lymphoma, multiple myeloma, neuroblastoma, glioma, glioblastoma multiforme, ovarian cancer, rhabdomyosarcoma, primary thrombocytosis, primary macroglobulinemia, primary brain tumors, cancer, malignant pancreatic insulanoma, malignant carcinoid, urinary bladder cancer, premalignant skin lesions, testicular cancer, lymphomas, thyroid cancer, neuroblastoma, esophageal cancer, genitourinary tract cancer, malignant hypercalcemia, endometrial cancer, adrenal cortical cancer
  • sarcoma generally refers to a tumor which is made up of a substance like the embryonic connective tissue and is generally composed of closely packed cells embedded in a fibrillar or homogeneous substance.
  • Sarcomas that may be treated with a compound, pharmaceutical composition, or method provided herein include a chondrosarcoma, fibrosarcoma, lymphosarcoma, melanosarcoma, myxosarcoma, osteosarcoma, Abemethy's sarcoma, adipose sarcoma, liposarcoma, alveolar soft part sarcoma, ameloblastic sarcoma, botryoid sarcoma, chloroma sarcoma, chorio carcinoma, embryonal sarcoma, Wilms' tumor sarcoma, endometrial sarcoma, stromal sarcoma, Ewing's sarcoma, fascial sar
  • carcinoma refers to a malignant new growth made up of epithelial cells tending to infiltrate the surrounding tissues and give rise to metastases.
  • exemplary carcinomas that may be treated with a compound, pharmaceutical composition, or method provided herein include, for example, medullary thyroid carcinoma, familial medullary thyroid carcinoma, acinar carcinoma, acinous carcinoma, adenocystic carcinoma, adenoid cystic carcinoma, carcinoma adenomatosum, carcinoma of adrenal cortex, alveolar carcinoma, alveolar cell carcinoma, basal cell carcinoma, carcinoma basocellulare, basaloid carcinoma, basosquamous cell carcinoma, bronchioalveolar carcinoma, bronchiolar carcinoma, bronchogenic carcinoma, cerebriform carcinoma, cholangiocellular carcinoma, chorionic carcinoma, colloid carcinoma, comedo carcinoma, corpus carcinoma, cribriform carcinoma, carcinoma en cuirasse, carcinoma cutaneum, cylindrical carcinoma, cylindrical cell carcinoma, duct carcinoma, ductal carcinoma, carcinoma durum, embryonal carcinoma
  • an “effective amount” is an amount sufficient to accomplish a stated purpose (e.g. achieve the effect for which it is administered, treat a disease, reduce enzyme activity, increase enzyme activity, reduce protein function, reduce one or more symptoms of a disease or condition).
  • An example of an “effective amount” is an amount sufficient to contribute to the treatment, prevention, or reduction of a symptom or symptoms of a disease, which could also be referred to as a “therapeutically effective amount.”
  • a “reduction” of a symptom or symptoms means decreasing of the severity or frequency of the symptom(s), or elimination of the symptom(s).
  • a “prophylactically effective amount” of a drug or prodrug is an amount of a drug or prodrug that, when administered to a subject, will have the intended prophylactic effect, e.g., preventing or delaying the onset (or reoccurrence) of an injury, disease, pathology or condition, or reducing the likelihood of the onset (or reoccurrence) of an injury, disease, pathology, or condition, or their symptoms.
  • the full prophylactic effect does not necessarily occur by administration of one dose, and may occur only after administration of a series of doses.
  • a prophylactically effective amount may be administered in one or more administrations.
  • a disease e.g. cancer, ovarian cancer, bladder cancer, head and neck cancer, brain cancer, breast cancer, lung cancer, cervical cancer, liver cancer, colorectal cancer, pancreatic cancer, glioblastoma, neuroblastoma, rhabdomyosarcoma, osteosarcoma, renal cancer, renal cell carcinoma, non-small cell lung cancer, uterine cancer, testicular cancer, anal cancer, bile duct cancer, biliary tract cancer, gastrointestinal carcinoid tumors, esophageal cancer, gall bladder cancer, appendix cancer, small intestine cancer, stomach (gastric) cancer, urinary bladder cancer, genitourinary tract cancer, endometrial cancer, nasopharyngeal cancer, head and neck squamous cell carcinoma, or prostate cancer
  • a disease e.g. cancer, ovarian cancer, bladder cancer, head and neck cancer, brain cancer, breast cancer, lung cancer, cervical cancer, liver cancer, colorectal cancer, pancre
  • cancer may be treated with a composition (e.g. compound, composition, nanoparticle, or conjugate, all as described herein) effective for inhibiting DNA replication.
  • a composition e.g. compound, composition, nanoparticle, or conjugate, all as described herein
  • Control or “control experiment” or “standard control” is used in accordance with its plain ordinary meaning and refers to an experiment in which the subjects or reagents of the experiment are treated as in a parallel experiment except for omission of a procedure, reagent, or variable of the experiment. In some instances, the control is used as a standard of comparison in evaluating experimental effects.
  • Contacting is used in accordance with its plain ordinary meaning and refers to the process of allowing at least two distinct species (e.g. chemical compounds including biomolecules, or cells) to become sufficiently proximal to react, interact or physically touch. It should be appreciated, however, that the resulting reaction product can be produced directly from a reaction between the added reagents or from an intermediate from one or more of the added reagents which can be produced in the reaction mixture.
  • the term “contacting” may include allowing two species to react, interact, or physically touch, wherein the two species may be a compound as described herein and a protein or enzyme. In some embodiments contacting includes allowing a compound described herein to interact with a protein.
  • inhibition means negatively affecting (e.g. decreasing) the level of activity or function of the protein relative to the level of activity or function of the protein in the absence of the inhibitor.
  • inhibition refers to a decrease in DNA replication or transcription.
  • inhibition refers to reduction of a disease or symptoms of disease (e.g.
  • inhibition may include, at least in part, partially or totally blocking stimulation, decreasing, preventing, or delaying activation, or inactivating, desensitizing, or down-regulating signal transduction or enzymatic activity or the amount of
  • activation means positively affecting (e.g. increasing) the activity or function of the protein relative to the activity or function of the protein in the absence of the activator (e.g. compound described herein).
  • activation may include, at least in part, partially or totally increasing stimulation, increasing or enabling activation, or activating, sensitizing, or up-regulating signal transduction or enzymatic activity or the amount of a protein decreased in a disease.
  • Activation may include, at least in part, partially or totally increasing stimulation, increasing or enabling activation, or activating, sensitizing, or up-regulating signal transduction or enzymatic activity or the amount of a protein.
  • modulator refers to a composition that increases or decreases the level of a target molecule or the function of a target molecule.
  • “Patient” or “subject in need thereof” or “subject” refers to a living organism suffering from or prone to a disease or condition that can be treated by administration of a compound or pharmaceutical composition or by a method, as provided herein.
  • Non-limiting examples include humans, other mammals, bovines, rats, mice, dogs, monkeys, goat, sheep, cows, deer, and other non-mammalian animals.
  • a patient is human.
  • a subject is human.
  • Disease or “condition” refer to a state of being or health status of a patient or subject capable of being treated with a compound, pharmaceutical composition, or method provided herein.
  • the disease is cancer.
  • the disease is ovarian cancer, bladder cancer, head and neck cancer, brain cancer, breast cancer, lung cancer, cervical cancer, liver cancer, colorectal cancer, pancreatic cancer, glioblastoma, neuroblastoma, rhabdomyosarcoma, osteosarcoma, renal cancer, renal cell carcinoma, non-small cell lung cancer, uterine cancer, testicular cancer, anal cancer, bile duct cancer, biliary tract cancer, gastrointestinal carcinoid tumors, esophageal cancer, gall bladder cancer, appendix cancer, small intestine cancer, stomach (gastric) cancer, urinary bladder cancer, genitourinary tract cancer, endometrial cancer, nasopharyngeal cancer, head and neck squamous cell carcinoma, or prostate cancer
  • “Pharmaceutically acceptable excipient” and “pharmaceutically acceptable carrier” refer to a substance that aids the administration of an active agent to and absorption by a subject and can be included in the compositions of the present invention without causing a significant adverse toxicological effect on the patient.
  • Non-limiting examples of pharmaceutically acceptable excipients include water, NaCl, normal saline solutions, lactated Ringer's, normal sucrose, normal glucose, binders, fillers, disintegrants, lubricants, coatings, sweeteners, flavors, salt solutions (such as Ringer's solution), alcohols, oils, gelatins, carbohydrates such as lactose, amylose or starch, fatty acid esters, hydroxymethycellulose, polyvinyl pyrrolidine, and colors, and the like.
  • Such preparations can be sterilized and, if desired, mixed with auxiliary agents such as lubricants, preservatives, stabilizers, wetting agents, emulsifiers, salts for influencing osmotic pressure, buffers, coloring, and/or aromatic substances and the like that do not deleteriously react with the compounds of the invention.
  • auxiliary agents such as lubricants, preservatives, stabilizers, wetting agents, emulsifiers, salts for influencing osmotic pressure, buffers, coloring, and/or aromatic substances and the like that do not deleteriously react with the compounds of the invention.
  • auxiliary agents such as lubricants, preservatives, stabilizers, wetting agents, emulsifiers, salts for influencing osmotic pressure, buffers, coloring, and/or aromatic substances and the like that do not deleteriously react with the compounds of the invention.
  • auxiliary agents such as lubricants, preservatives, stabilizers, wetting agents
  • preparation is intended to include the formulation of the active compound with encapsulating material as a carrier providing a capsule in which the active component with or without other carriers, is surrounded by a carrier, which is thus in association with it.
  • carrier providing a capsule in which the active component with or without other carriers, is surrounded by a carrier, which is thus in association with it.
  • cachets and lozenges are included. Tablets, powders, capsules, pills, cachets, and lozenges can be used as solid dosage forms suitable for oral administration.
  • administering means oral administration, administration as a suppository, topical contact, intravenous, parenteral, intraperitoneal, intramuscular, intralesional, intrathecal, intracranial, intranasal or subcutaneous administration, or the implantation of a slow-release device, e.g., a mini-osmotic pump, to a subject.
  • Administration is by any route, including parenteral and transmucosal (e.g., buccal, sublingual, palatal, gingival, nasal, vaginal, rectal, or transdermal).
  • Parenteral administration includes, e.g., intravenous, intramuscular, intra-arteriole, intradermal, subcutaneous, intraperitoneal, intraventricular, and intracranial.
  • Other modes of delivery include, but are not limited to, the use of liposomal formulations, intravenous infusion, transdermal patches, etc.
  • co-administer it is meant that a composition described herein is administered at the same time, just prior to, or just after the administration of one or more additional therapies.
  • the compound of the invention can be administered alone or can be coadministered to the patient.
  • Coadministration is meant to include simultaneous or sequential administration of the compound individually or in combination (more than one compound or agent).
  • the preparations can also be combined, when desired, with other active substances (e.g.
  • compositions of the present invention can be delivered by transdermally, by a topical route, formulated as applicator sticks, solutions, suspensions, emulsions, gels, creams, ointments, pastes, jellies, paints, powders, and aerosols.
  • Oral preparations include tablets, pills, powder, dragees, capsules, liquids, lozenges, cachets, gels, syrups, slurries, suspensions, etc., suitable for ingestion by the patient.
  • Solid form preparations include powders, tablets, pills, capsules, cachets, suppositories, and dispersible granules.
  • Liquid form preparations include solutions, suspensions, and emulsions, for example, water or water/propylene glycol solutions.
  • the compositions of the present invention may additionally include components to provide sustained release and/or comfort.
  • Such components include high molecular weight, anionic mucomimetic polymers, gelling polysaccharides and finely-divided drug carrier substrates. These components are discussed in greater detail in U.S. Pat. Nos. 4,911,920; 5,403,841; 5,212,162; and 4,861,760. The entire contents of these patents are incorporated herein by reference in their entirety for all purposes.
  • the compositions of the present invention can also be delivered as microspheres for slow release in the body.
  • microspheres can be administered via intradermal injection of drug-containing microspheres, which slowly release subcutaneously (see Rao, J. Biomater Sci. Polym. Ed. 7:623-645, 1995; as biodegradable and injectable gel formulations (see, e.g., Gao Pharm. Res. 12:857-863, 1995); or, as microspheres for oral administration (see, e.g., Eyles, J. Pharm. Pharmacol. 49:669-674, 1997).
  • the formulations of the compositions of the present invention can be delivered by the use of liposomes which fuse with the cellular membrane or are endocytosed, i.e., by employing receptor ligands attached to the liposome, that bind to surface membrane protein receptors of the cell resulting in endocytosis.
  • liposomes particularly where the liposome surface carries receptor ligands specific for target cells, or are otherwise preferentially directed to a specific organ, one can focus the delivery of the compositions of the present invention into the target cells in vivo.
  • the compositions of the present invention can also be delivered as nanoparticles.
  • compositions provided by the present invention include compositions wherein the active ingredient (e.g. compounds described herein, including embodiments or examples) may be contained in a therapeutically effective amount, i.e., in an amount effective to achieve its intended purpose.
  • the actual amount effective for a particular application will depend, inter alia, on the condition being treated.
  • Such compositions When administered in methods to treat a disease, such compositions will contain an amount of active ingredient effective to achieve the desired result, e.g., reducing, eliminating, or slowing the progression of disease symptoms. Determination of a therapeutically effective amount of a compound of the invention is well within the capabilities of those skilled in the art, especially in light of the detailed disclosure herein.
  • the dosage and frequency (single or multiple doses) administered to a mammal can vary depending upon a variety of factors, for example, whether the mammal suffers from another disease, and its route of administration; size, age, sex, health, body weight, body mass index, and diet of the recipient; nature and extent of symptoms of the disease being treated, kind of concurrent treatment, complications from the disease being treated or other health-related problems.
  • Other therapeutic regimens or agents can be used in conjunction with the methods and compounds of Applicants' invention. Adjustment and manipulation of established dosages (e.g., frequency and duration) are well within the ability of those skilled in the art.
  • the therapeutically effective amount can be initially determined from cell culture assays.
  • Target concentrations will be those concentrations of active compound(s) that are capable of achieving the methods described herein, as measured using the methods described herein or known in the art.
  • therapeutically effective amounts for use in humans can also be determined from animal models.
  • a dose for humans can be formulated to achieve a concentration that has been found to be effective in animals.
  • the dosage in humans can be adjusted by monitoring compounds effectiveness and adjusting the dosage upwards or downwards, as described above. Adjusting the dose to achieve maximal efficacy in humans based on the methods described above and other methods is well within the capabilities of the ordinarily skilled artisan.
  • Dosages may be varied depending upon the requirements of the patient and the compound being employed.
  • the dose administered to a patient, in the context of the present invention should be sufficient to affect a beneficial therapeutic response in the patient over time.
  • the size of the dose also will be determined by the existence, nature, and extent of any adverse side-effects. Determination of the proper dosage for a particular situation is within the skill of the practitioner. Generally, treatment is initiated with smaller dosages which are less than the optimum dose of the compound. Thereafter, the dosage is increased by small increments until the optimum effect under circumstances is reached.
  • Dosage amounts and intervals can be adjusted individually to provide levels of the administered compound effective for the particular clinical indication being treated. This will provide a therapeutic regimen that is commensurate with the severity of the individual's disease state.
  • an effective prophylactic or therapeutic treatment regimen can be planned that does not cause substantial toxicity and yet is effective to treat the clinical symptoms demonstrated by the particular patient.
  • This planning should involve the careful choice of active compound by considering factors such as compound potency, relative bioavailability, patient body weight, presence and severity of adverse side effects, preferred mode of administration and the toxicity profile of the selected agent.
  • the compounds described herein can be used in combination with one another, with other active agents (e.g. anti-cancer agents) known to be useful in treating a disease described herein (e.g. ovarian cancer, bladder cancer, head and neck cancer, brain cancer, breast cancer, lung cancer, cervical cancer, liver cancer, colorectal cancer, pancreatic cancer, glioblastoma, neuroblastoma, rhabdomyosarcoma, osteosarcoma, renal cancer, renal cell carcinoma, non-small cell lung cancer, uterine cancer, testicular cancer, anal cancer, bile duct cancer, biliary tract cancer, gastrointestinal carcinoid tumors, esophageal cancer, gall bladder cancer, appendix cancer, small intestine cancer, stomach (gastric) cancer, urinary bladder cancer, genitourinary tract cancer, endometrial cancer, nasopharyngeal cancer, head and neck squamous cell carcinoma, or prostate cancer), or with adjunctive agents that may not be effective alone
  • co-administration includes administering one active agent within 0.5, 1, 2, 4, 6, 8, 10, 12, 16, 20, or 24 hours of a second active agent (e.g. anti-cancer agent).
  • Co-administration includes administering two active agents simultaneously, approximately simultaneously (e.g., within about 1, 5, 10, 15, 20, or 30 minutes of each other), or sequentially in any order.
  • co-administration can be accomplished by co-formulation, i.e., preparing a single pharmaceutical composition including both active agents.
  • the active agents can be formulated separately.
  • the active and/or adjunctive agents may be linked or conjugated to one another.
  • Anti-cancer agent is used in accordance with its plain ordinary meaning and refers to a composition (e.g. compound, drug, antagonist, inhibitor, modulator) having antineoplastic properties or the ability to inhibit the growth or proliferation of cells.
  • an anti-cancer agent is a chemotherapeutic.
  • an anti-cancer agent is an agent identified herein having utility in methods of treating cancer.
  • an anti-cancer agent is an agent approved by the FDA or similar regulatory agency of a country other than the USA, for treating cancer. Examples of anti-cancer agents include, but are not limited to, MEK (e.g. MEK1, MEK2, or MEK1 and MEK2) inhibitors (e.g.
  • alkylating agents e.g., cyclophosphamide, ifosfamide, chlorambucil, busulfan, melphalan, mechlorethamine, uramustine, thiotepa, nitrosoureas, nitrogen mustards (e.g., mechloroethamine, cyclophosphamide, chlorambucil, meiphalan), ethylenimine and methylmelamines (e.g., hexamethlymelamine, thiotepa), alkyl sulfonates (e.g., cyclophosphamide, ifosfamide, chlorambucil, busulfan, melphalan, mechlorethamine, uramustine, thiotepa, nitrosoureas, nitrogen mustards (e.g., mechloroethamine, cyclophosphamide, chlorambucil, meiphalan),
  • TaxolTM i.e. paclitaxel
  • TaxotereTM compounds comprising the taxane skeleton, Erbulozole (i.e. R-55104), Dolastatin 10 (i.e. DLS-10 and NSC-376128), Mivobulin isethionate (i.e. as CI-980), Vincristine, NSC-639829, Discodermolide (i.e. as NVP-XX-A-296), ABT-751 (Abbott, i.e. E-7010), Altorhyrtins (e.g. Altorhyrtin A and Altorhyrtin C), Spongistatins (e.g.
  • Altorhyrtins e.g. Altorhyrtin A and Altorhyrtin C
  • Spongistatins e.g.
  • Epothilone E Epothilone F
  • Epothilone B N-oxide Epothilone A N-oxide
  • 16-aza-epothilone B Epothilone B
  • 21-aminoepothilone B i.e. BMS-310705
  • 21-hydroxyepothilone D i.e. Desoxyepothilone F and dEpoF
  • 26-fluoroepothilone i.e. NSC-654663
  • Soblidotin i.e. TZT-1027
  • Vincristine sulfate i.e.
  • LY-355703 Vitilevuamide, Tubulysin A, Canadensol, Centaureidin (i.e. NSC-106969), Oncocidin A1 (i.e. BTO-956 and DIME), Fijianolide B, Laulimalide, Narcosine (also known as NSC-5366), Nascapine, Hemiasterlin, Vanadocene acetylacetonate, Monsatrol, lnanocine (i.e.
  • Eleutherobins such as Desmethyleleutherobin, Desaetyleleutherobin, lsoeleutherobin A, and Z-Eleutherobin
  • Caribaeoside Caribaeolin
  • Halichondrin B Diazonamide A
  • Taccalonolide A Diozostatin
  • ( ⁇ )-Phenylahistin i.e.
  • NSCL-96F03-7 Myoseverin B, Resverastatin phosphate sodium, steroids (e.g., dexamethasone), finasteride, aromatase inhibitors, gonadotropin-releasing hormone agonists (GnRH) such as goserelin or leuprolide, adrenocorticosteroids (e.g., prednisone), progestins (e.g., hydroxyprogesterone caproate, megestrol acetate, medroxyprogesterone acetate), estrogens (e.g., diethlystilbestrol, ethinyl estradiol), antiestrogen (e.g., tamoxifen), androgens (e.g., testosterone propionate, fluoxymesterone), antiandrogen (e.g., flutamide), immunostimulants (e.g., Bacillus Calmette-Guérin (BCG), levamisole, interleuk
  • gefitinib IressaTM
  • erlotinib TarcevaTM
  • cetuximab ErbituxTM
  • lapatinib TykerbTM
  • panitumumab VectibixTM
  • vandetanib CaprelsaTM
  • afatinib/BIBW2992 CI-1033/canertinib, neratinib/HKI-272, CP-724714, TAK-285, AST-1306, ARRY334543, ARRY-380, AG-1478, dacomitinib/PF299804, OSI-420/desmethyl erlotinib, AZD8931, AEE788, pelitinib/EKB-569, CUDC-101, WZ8040, WZ4002, WZ3146, AG-490, XL647, PD153035, BMS-599626), sorafenib, imatinib, sunitinib, dasat
  • the term “about” means a range of values including the specified value, which a person of ordinary skill in the art would consider reasonably similar to the specified value. In embodiments, about means within a standard deviation using measurements generally acceptable in the art. In embodiments, about means a range extending to +/ ⁇ 10% of the specified value. In embodiments, about means the specified value.
  • amino acid refers to naturally occurring and synthetic amino acids, as well as amino acid analogs and amino acid mimetics that function in a manner similar to the naturally occurring amino acids.
  • Naturally occurring amino acids are those encoded by the genetic code, as well as those amino acids that are later modified, e.g., hydroxyproline, ⁇ -carboxyglutamate, and O-phosphoserine.
  • Amino acid analogs refers to compounds that have the same basic chemical structure as a naturally occurring amino acid, i.e., an a carbon that is bound to a hydrogen, a carboxyl group, an amino group, and an R group, e.g., homoserine, norleucine, methionine sulfoxide, methionine methyl sulfonium. Such analogs have modified R groups (e.g., norleucine) or modified peptide backbones, but retain the same basic chemical structure as a naturally occurring amino acid.
  • Amino acid mimetics refers to chemical compounds that have a structure that is different from the general chemical structure of an amino acid, but that functions in a manner similar to a naturally occurring amino acid.
  • non-naturally occurring amino acid and “unnatural amino acid” refer to amino acid analogs, synthetic amino acids, and amino acid mimetics which are not found in nature.
  • Sulfur-containing amino acids refers to naturally occurring and synthetic amino acids comprising sulfur, e.g., methionine, cysteine, homocysteine, and taurine.
  • Amino acids may be referred to herein by either their commonly known three letter symbols or by the one-letter symbols recommended by the IUPAC-IUB Biochemical Nomenclature Commission. Nucleotides, likewise, may be referred to by their commonly accepted single-letter codes.
  • bioconjugate or “bioconjugate linker” refers to the resulting association between atoms or molecules of bioconjugate reactive groups.
  • the association can be direct or indirect.
  • a conjugate between a first bioconjugate reactive group e.g. —NH 2 , —COOH, —N-hydroxysuccinimide, or -maleimide
  • a second bioconjugate reactive group e.g., sulfhydryl, sulfur-containing amino acid, amine, amine sidechain containing amino acid, or carboxylate
  • covalent bond or linker e.g.
  • bioconjugates or bioconjugate linkers are formed using bioconjugate chemistry (i.e.
  • bioconjugate reactive groups including, but are not limited to nucleophilic substitutions (e.g., reactions of amines and alcohols with acyl halides, active esters), electrophilic substitutions (e.g., enamine reactions) and additions to carbon-carbon and carbon-heteroatom multiple bonds (e.g., Michael reaction, Diels-Alder addition).
  • nucleophilic substitutions e.g., reactions of amines and alcohols with acyl halides, active esters
  • electrophilic substitutions e.g., enamine reactions
  • additions to carbon-carbon and carbon-heteroatom multiple bonds e.g., Michael reaction, Diels-Alder addition.
  • the first bioconjugate reactive group e.g., maleimide moiety
  • the second bioconjugate reactive group e.g. a sulfhydryl
  • the first bioconjugate reactive group (e.g., haloacetyl moiety) is covalently attached to the second bioconjugate reactive group (e.g. a sulfhydryl).
  • the first bioconjugate reactive group (e.g., pyridyl moiety) is covalently attached to the second bioconjugate reactive group (e.g. a sulfhydryl).
  • the first bioconjugate reactive group e.g., —N-hydroxysuccinimide moiety
  • is covalently attached to the second bioconjugate reactive group (e.g. an amine).
  • the first bioconjugate reactive group (e.g., maleimide moiety) is covalently attached to the second bioconjugate reactive group (e.g. a sulfhydryl).
  • the first bioconjugate reactive group (e.g., -sulfo-N-hydroxysuccinimide moiety) is covalently attached to the second bioconjugate reactive group (e.g. an amine).
  • haloacetyl refers to a functional group having the formula:
  • bioconjugate reactive groups used for bioconjugate chemistries herein include, for example:
  • bioconjugate reactive groups can be chosen such that they do not participate in, or interfere with, the chemical stability of the conjugate described herein.
  • a reactive functional group can be protected from participating in the crosslinking reaction by the presence of a protecting group.
  • the bioconjugate comprises a molecular entity derived from the reaction of an unsaturated bond, such as a maleimide, and a sulfhydryl group.
  • a cell can be identified by well-known methods in the art including, for example, presence of an intact membrane, staining by a particular dye, ability to produce progeny or, in the case of a gamete, ability to combine with a second gamete to produce a viable offspring.
  • Cells may include prokaryotic and eukaroytic cells.
  • Prokaryotic cells include but are not limited to bacteria.
  • Eukaryotic cells include but are not limited to yeast cells and cells derived from plants and animals, for example mammalian, insect (e.g., spodoptera) and human cells. Cells may be useful when they are naturally nonadherent or have been treated not to adhere to surfaces, for example by trypsinization.
  • a neural stem cell is a tropic stem cell that can self-renew and give rise to differentiated progenitor cells, such as HB1.F3 neural stem cells.
  • Nanoparticle is a particle wherein the longest diameter is less than or equal to 1000 nanometers.
  • Nanoparticles may be composed of any appropriate material.
  • nanoparticle cores may include appropriate metals and metal oxides thereof (e.g., a metal nanoparticle core), carbon (e.g., an organic nanoparticle core) silicon and oxides thereof (e.g., a silicon nanoparticle core) or boron and oxides thereof (e.g., a boron nanoparticle core), or mixtures thereof.
  • Nanoparticles may be composed of at least two distinct materials, one material (e.g., iron oxide) forms the core and the other material forms the shell (e.g., silica) surrounding the core.
  • an “inorganic nanoparticle” refers to a nanoparticle without carbon.
  • an inorganic nanoparticle may refer to a metal or metal oxide thereof (e.g., gold nanoparticle, iron nanoparticle) silicon and oxides thereof (e.g., a silica nanoparticle), or titanium and oxides thereof (e.g., titanium dioxide nanoparticle).
  • the inorganic nanoparticle is a silica nanoparticle.
  • the inorganic nanoparticle may be a metal nanoparticle.
  • the metal may be titanium, zirconium, gold, silver, platinum, cerium, arsenic, iron, aluminum or silicon.
  • the metal nanoparticle may be titanium, zirconium, gold, silver, or platinum and appropriate metal oxides thereof.
  • the nanoparticle is titanium oxide, zirconium oxide, cerium oxide, arsenic oxide, iron oxide, aluminum oxide, or silicon oxide.
  • the metal oxide nanoparticle may be titanium oxide or zirconium oxide.
  • the nanoparticle may be titanium.
  • the nanoparticle may be gold.
  • the metal nanoparticle is a gold nanoparticle.
  • the inorganic nanoparticle may further include a moiety which contains carbon (e.g., carboplatin).
  • silica nanoparticle is used according to its plain and ordinary meaning and refers to a nanoparticle containing Si atoms (e.g., in a tetrahedral coordination) with 4 oxygen atoms surrounding a central Si atom.
  • the silica nanoparticle typically includes terminal oxygen atoms (e.g., the oxygens on the surface of the nanoparticle) that are hydroxyl moieties.
  • a silica nanoparticle is a particle wherein the longest diameter is typically less than or equal to 1000 nanometers comprising a matrix of silicon-oxygen bonds.
  • the silica nanoparticle includes a platinum anti-cancer agent
  • one or more of the silicon oxygen bonds within the silica nanoparticle may be replaced, with the Si atom bonded to platinum either directly (i.e., a Pt—Si bond), though an oxygen linker (i.e., an oxygen bound to Si, thereby forming a —Si—O—Pt— bond), or through a nitrogen linker (i.e., a nitrogen bound to Si, thereby forming an —Si—NH—Pt— bond) as described herein.
  • a nanoparticle has a shortest diameter greater than or equal to 1 nanometer (e.g., diameter from 1 to 1000 nanometers).
  • the silica nanoparticle is mesoporous. In embodiments, the silica nanoparticle is nonporous.
  • a functionalized silica nanoparticle may refer to the post hoc conjugation (i.e. conjugation after the formation of the silica nanoparticle) of a moiety to the hydroxyl surface of a nanoparticle.
  • a silica nanoparticle may be further functionalized to include additional atoms (e.g., nitrogen) or chemical entities (e.g., polymeric moieties or bioconjugate group).
  • additional atoms e.g., nitrogen
  • chemical entities e.g., polymeric moieties or bioconjugate group
  • one of the surface oxygen atoms surrounding the Si atom may be replaced with a nitrogen containing moiety.
  • an unmodified silica nanoparticle refers to a silica nanoparticle which has not been further functionalized.
  • an unmodified silica nanoparticle does not include a nitrogen containing moiety (e.g., terminal amine moieties).
  • an unmodified silica nanoparticle refers to a silica nanoparticle as synthesized without post hoc functionalization.
  • the unmodified silica nanoparticles includes the following example:
  • bare silica nanoparticle and “unmodified silica nanoparticle” are synonymous and interchangeable.
  • platinum anti-cancer agent is used in accordance with its common meaning and refers to an anti-cancer agent including coordinated platinum.
  • a platinum anti-cancer agent may be cisplatin, carboplatin, oxaliplatin, satraplatin, lobaplatin, picoplatin, heptaplatin, nedaplatin, triplatin, or a platinum containing compound described herein.
  • a platinum anti-cancer agent includes a platinum salt (e.g, K 2 [PtCl 4 ]).
  • the platinum anti-cancer agent is a platinum anti-cancer agent described in U.S. Pat. No. 8,455,543, which is incorporated herein in its entirety for all purposes.
  • a “detectable agent” or “detectable compound” is a composition detectable by spectroscopic, photochemical, biochemical, immunochemical, chemical, magnetic resonance imaging, or other physical means.
  • useful detectable agents include 18 F, 32 P, 33 P, 45 Ti, 47 Sc, 52 Fe, 59 Fe, 62 Cu, 64 Cu, 67 Cu, 67 Ga, 68 Ga, 77 As, 86 Y, 90 Y, 89 Sr, 89 Zr, 94 Tc, 94 Tc, 99m Tc, 99 Mo, 105 Pd, 105 Rh 111 Ag, 111 In, 123 I, 124 I, 125 I, 131 I, 142 Pr, 143 Pr, 149 Pm, 153 Sm, 154-1581 Gd, 161 Tb, 166 Dy, 166 Ho, 169 Er, 175 Lu, 177 Lu, 186 Re, 188 Re, 189 Re, 194 I, 198 Au, 199 Au, 211 At, 211 Pb, 212 Bi,
  • fluorescent dyes include fluorescent dyes), electron-dense reagents, enzymes (e.g., as commonly used in an ELISA), biotin, digoxigenin, paramagnetic molecules, paramagnetic nanoparticles, ultrasmall superparamagnetic iron oxide (“USPIO”) nanoparticles, USPIO nanoparticle aggregates, superparamagnetic iron oxide (“SPIO”) nanoparticles, SPIO nanoparticle aggregates, monochrystalline iron oxide nanoparticles, monochrystalline iron oxide, nanoparticle contrast agents, liposomes or other delivery vehicles containing Gadolinium chelate (“Gd-chelate”) molecules, Gadolinium, radioisotopes, radionuclides (e.g.
  • microbubbles e.g. including microbubble shells including albumin, galactose, lipid, and/or polymers; microbubble gas core including air, heavy gas(es), perfluorcarbon, nitrogen, octafluoropropane, perflexane lipid microsphere, perflutren, etc.
  • iodinated contrast agents e.g.
  • a detectable moiety is a monovalent detectable agent or a detectable agent capable of forming a bond with another composition (e.g., a nanoparticle or silica nanoparticle).
  • Radioactive substances e.g., radioisotopes
  • Radioactive substances include, but are not limited to, 18 F, 32 P, 33 P, 45 Ti, 47 Sc, 52 Fe, 59 Fe, 62 Cu, 64 Cu 67 Cu, 67 Ga, 68 Ga, 77 As, 86 Y, 90 Y.
  • Paramagnetic ions that may be used as additional imaging agents in accordance with the embodiments of the disclosure include, but are not limited to, ions of transition and lanthanide metals (e.g. metals having atomic numbers of 21-29, 42, 43, 44, or 57-71). These metals include ions of Cr, V, Mn, Fe, Co, Ni, Cu, La, Ce, Pr, Nd, Pm, Sm, Eu, Gd, Tb, Dy, Ho, Er, Tm, Yb and Lu.
  • transition and lanthanide metals e.g. metals having atomic numbers of 21-29, 42, 43, 44, or 57-71.
  • These metals include ions of Cr, V, Mn, Fe, Co, Ni, Cu, La, Ce, Pr, Nd, Pm, Sm, Eu, Gd, Tb, Dy, Ho, Er, Tm, Yb and Lu.
  • detectable agents include imaging agents, including fluorescent and luminescent substances, including, but not limited to, a variety of organic or inorganic small molecules commonly referred to as “dyes,” “labels,” or “indicators.” Examples include fluorescein, rhodamine, acridine dyes, Alexa dyes, and cyanine dyes. Enzymes that may be used as imaging agents in accordance with the embodiments of the disclosure include, but are not limited to, horseradish peroxidase, alkaline phosphatase, acid phoshatase, glucose oxidase, ⁇ -galactosidase, ⁇ -glucoronidase or ⁇ -lactamase. Such enzymes may be used in combination with a chromogen, a fluorogenic compound or a luminogenic compound to generate a detectable signal.
  • polymeric refers to a molecule including repeating subunits (e.g., polymerized monomers).
  • polymeric molecules may be based upon polyethylene glycol (PEG), poly[amino(1-oxo-1,6-hexanediyl)], or poly(oxy-1,2-ethanediyloxycarbonyl-1,4-phenylenecarbonyl).
  • PEG polyethylene glycol
  • poly[amino(1-oxo-1,6-hexanediyl)] or poly(oxy-1,2-ethanediyloxycarbonyl-1,4-phenylenecarbonyl).
  • polymerizable monomer is used in accordance with its meaning in the art of polymer chemistry and refers to a compound that may covalently bind chemically to other monomer molecules (such as other polymerizable monomers that are the same or different) to form a polymer.
  • branched polymer is used in accordance with its meaning in the art of polymer chemistry and refers to a molecule including repeating subunits, wherein at least one repeating subunit (e.g., polymerizable monomer) is covalently bound to a different subunit (e.g., polymerizable monomer).
  • a branched polymer has the formula:
  • ‘A’ is the first repeating subunit and ‘B’ is the second repeating subunit.
  • the first repeating subunit e.g., polyethylene glycol
  • the second repeating subunit e.g., polymethylene glycol
  • unmodified platinum anti-cancer agent refers to a platinum anti-cancer agent which is not modified prior to incorporation into the silica nanoparticle, wherein the platinum anti-cancer agent is conjugated to silica directly, though an oxygen linker, or through a nitrogen linker.
  • the resulting nanoparticle may be referred to as including an “unmodified platinum anti-cancer agent” even though the platinum anti-cancer agent may have reacted with a portion of the silica nanoparticle during or subsequent to the incorporation process.
  • a silica nanoparticle including a platinum anti-cancer agent, wherein the platinum anti-cancer agent is conjugated to silica directly (i.e., a Pt—Si bond), the platinum anti-cancer agent is conjugated to silica though an oxygen linker (i.e., an oxygen bound to Si, thereby forming a —Si—O—Pt— bond), or the platinum anti-cancer agent is conjugated to silica through a nitrogen linker (i.e., a nitrogen bound to Si, thereby forming an —Si—NH—Pt— bond).
  • the platinum is conjugated directly to the Si atom thereby forming a —Si—Pt— bond.
  • the platinum is conjugated directly to one or more Si atoms. In embodiments, the platinum is conjugated to the Si atom via an oxygen linker thereby forming a —Si—O—Pt— bond. In embodiments, the platinum is conjugated to the Si atom via one or more oxygen linkers. In embodiments, the platinum is conjugated to the Si atom via a nitrogen linker thereby forming a —Si—NH—Pt— bond. In embodiments, the platinum is conjugated to the Si atom via one or more a nitrogen linkers. In embodiments, the platinum anti-cancer agent is conjugated to an oxygen donor within the silica nanoparticle.
  • the platinum anti-cancer agent is conjugated to one or more oxygen donors within the silica nanoparticle.
  • the platinum anti-cancer agent is not conjugated to the silica nanoparticle via an aminosilane moiety (e.g., (3-aminopropyl) triethoxysilane).
  • the platinum anti-cancer agent is not conjugated to the silica nanoparticle via an ester, aminoalkyl, urea, thiourea, or thioether group.
  • the platinum atom of the platinum anti-cancer agent (e.g., platinum salt or cisplatin) within the silica nanoparticle is directly bonded to one or more oxygen donors within the silica nanoparticle (e.g. an oxygen of a silicon-oxygen moiety within the silica nanoparticle), having the formula:
  • the silica nanoparticle is an unmodified silica nanoparticle.
  • the silica nanoparticle is a non-polymeric functionalized silica nanoparticle (i.e. a silica nanoparticle that does not include polymers conjugated to the surface of the silica nanoparticle).
  • the silica nanoparticle is a non-pegylated functionalized silica nanoparticle (i.e. a silica nanoparticle that does not include PEG polymers conjugated to the surface of the silica nanoparticle).
  • the silica nanoparticle is a non-functionalized silica nanoparticle (i.e. a silica nanoparticle that does not include reactive chemical functional groups, such as a bioconjugate reactive group, conjugated to the surface of the silica nanoparticle (other than the terminal hydroxyl groups).
  • the unmodified silica nanoparticle includes terminal oxygen atoms (e.g., the oxygens on the surface of the nanoparticle) that are hydroxyl moieties.
  • the terminal oxygen atoms of the unmodified silica nanoparticle are —OH or salts thereof (e.g. —O ⁇ moieties).
  • the terminal oxygen atoms of the unmodified silica nanoparticle may include an —OR′′ moiety, wherein R′′ is a substituted (e.g., substituted with a substituent group, a size-limited substituent group, or lower substituent group) or unsubstituted alkyl, substituted (e.g., substituted with a substituent group, a size-limited substituent group, or lower substituent group) or unsubstituted heteroalkyl, substituted (e.g., substituted with a substituent group, a size-limited substituent group, or lower substituent group) or unsubstituted cycloalkyl, substituted (e.g., substituted with a substituent group, a size-limited substituent group, or lower substituent group) or unsubstituted heterocycloalkyl, substituted (e.g., substituted with a substituent group, a size-limited substituent group, or lower substituent group) or unsubstituted heterocycl
  • the unmodified silica nanoparticle does not include a covalent bond to an additional chemical moiety (e.g., platinum anti-cancer agent).
  • the unmodified silica nanoparticle includes a covalent bond to an additional chemical moiety (e.g., platinum anti-cancer agent).
  • an additional chemical moiety e.g., platinum anti-cancer agent
  • no further chemistry is performed to attach an additional chemical moiety (e.g., platinum anti-cancer agent) to the surface of the nanoparticle.
  • the platinum anti-cancer agent is incorporated (e.g., covalently or non-covalently) within the silica nanoparticle.
  • the platinum anti-cancer agent is incorporated (e.g., covalently or non-covalently) throughout the silica nanoparticle (e.g., evenly distributed throughout the silica nanoparticle, distributed throughout the silica nanoparticle (e.g. in varying local concentrations), distributed within +/ ⁇ 10, 20, 30, 40, 50, 60, 70, 80, 90, or 100% of the average local concentration).
  • the platinum anti-cancer agent is distributed within about 10, 20, 30, 40, 50, 60, 70, 80, 90, or 100% of the average local concentration.
  • the platinum anti-cancer agent is conjugated to the surface and within the silica nanoparticle. In embodiments, the platinum anti-cancer agent is at the surface of the silica nanoparticle (e.g., bonded covalently or non-covalently).
  • the cisplatin is encapsulated within the silica nanoparticle (e.g., a particle of cisplatin within the nanoparticle (e.g., a particle of greater than 60, 70, 80, 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99% cisplatin or a particle of about 100% cisplatin)). In embodiments, the cisplatin is encapsulated within the silica nanoparticle and at the surface.
  • the platinum anti-cancer agent is not modified prior to incorporation into the silica nanoparticle (an “unmodified platinum anti-cancer agent”).
  • cisplatin may be incorporated into the silica nanoparticle in an unmodified form as (SP-4-2)-diamminedicholoroplatinum(II) (e.g,
  • the cisplatin may react with a portion of the silica nanoparticle.
  • one or more Pt ligands (e.g., —Cl) of cisplatin may be replaced with a bond directly to an oxygen of silica (e.g.,
  • the resulting nanoparticle may be referred to as including “unmodified cisplatin” even though the cisplatin may have reacted with a portion of the silica nanoparticle during or subsequent to the incorporation process.
  • the silica nanoparticle includes a platinum anti-cancer agent (e.g., unmodified platinum anti-cancer agent) such as an unmodified cisplatin.
  • the platinum anti-cancer agent is cisplatin, carboplatin, oxaliplatin, satraplatin, lobaplatin, picoplatin, heptaplatin, nedaplatin, or triplatin.
  • the platinum anti-cancer agent is cisplatin.
  • the cisplatin is directly conjugated to the silica nanoparticle.
  • the platinum anti-cancer agent is carboplatin.
  • the platinum anti-cancer agent is oxaliplatin.
  • the platinum anti-cancer agent is satraplatin.
  • the platinum anti-cancer agent is lobaplatin.
  • the platinum anti-cancer agent is picoplatin. In embodiments, the platinum anti-cancer agent is heptaplatin. In embodiments, the platinum anti-cancer agent is nedaplatin. In embodiments, the platinum anti-cancer agent is triplatin. In embodiments, the ligands of the platinum anti-cancer agent optionally replaced with water. In embodiments, the ligands of the platinum anti-cancer agent optionally replaced with an oxygen (e.g., an oxygen bound to silica) in the nanoparticle.
  • an oxygen e.g., an oxygen bound to silica
  • the platinum anti-cancer agent is a platinum salt.
  • the platinum anti-cancer agent is PtX 4 , wherein X is a halogen.
  • the platinum anti-cancer agent is PtCl 4 .
  • the platinum anti-cancer agent is [A 2 ]PtX 2 , wherein X is a halogen and A is a cation (e.g., potassium or sodium).
  • the platinum anti-cancer agent is PtX 2 , wherein X is a halogen.
  • the platinum anti-cancer agent is Pt(Cl) 2 .
  • the platinum anti-cancer agent is Pt(CN) 2 .
  • the platinum anti-cancer agent is ammonium hexachloroplatinate, ammonium tetrachloroplatinate, potassium trichloro(ethylene)platinate(II) hydrate, Zeise's salt, or hexachloroplatinic acid.
  • the platinum anti-cancer agent is [Pt(NH 3 ) 4 ]Cl 2 , K 2 [Pt(NO 2 ) 4 ], or platinum nitrate.
  • the silica:platinum mass ratio is about 10:1 to 100:1. In embodiments, the silica:platinum mass ratio is about 10:1 to 90:1. In embodiments, the silica:platinum mass ratio is about 10:1 to 80:1. In embodiments, the silica:platinum mass ratio is about 10:1 to 70:1. In embodiments, the silica:platinum mass ratio is about 10:1 to 60:1. In embodiments, the silica:platinum mass ratio is about 10:1 to 50:1.
  • the silica:platinum mass ratio is about 10:1 to 40:1. In embodiments, the silica:platinum mass ratio is about 11:1. In embodiments, the silica:platinum mass ratio is about 12:1. In embodiments, the silica:platinum mass ratio is about 13:1. In embodiments, the silica:platinum mass ratio is about 14:1. In embodiments, the silica:platinum mass ratio is about 15:1. In embodiments, the silica:platinum mass ratio is about 16:1. In embodiments, the silica:platinum mass ratio is about 17:1. In embodiments, the silica:platinum mass ratio is about 18:1.
  • the silica:platinum mass ratio is about 19:1. In embodiments, the silica:platinum mass ratio is about 20:1. In embodiments, the silica:platinum mass ratio is about 21:1. In embodiments, the silica:platinum mass ratio is about 22:1. In embodiments, the silica:platinum mass ratio is about 23:1. In embodiments, the silica:platinum mass ratio is about 24:1. In embodiments, the silica:platinum mass ratio is about 25:1. In embodiments, the silica:platinum mass ratio is about 26:1. In embodiments, the silica:platinum mass ratio is about 27:1. In embodiments, the silica:platinum mass ratio is about 28:1.
  • the silica:platinum mass ratio is about 29:1. In embodiments, the silica:platinum mass ratio is about 30:1. In embodiments, the silica:platinum mass ratio is about 31:1. In embodiments, the silica:platinum mass ratio is about 32:1. In embodiments, the silica:platinum mass ratio is about 33:1. In embodiments, the silica:platinum mass ratio is about 34:1. In embodiments, the silica:platinum mass ratio is about 35:1. In embodiments, the silica:platinum mass ratio is about 36:1. In embodiments, the silica:platinum mass ratio is about 37:1. In embodiments, the silica:platinum mass ratio is about 38:1. In embodiments, the silica:platinum mass ratio is about 39:1. In embodiments, the silica:platinum mass ratio is about 40:1.
  • the average longest dimension of the nanoparticle is from about 10 nm to about 1000 nm. In embodiments, the average longest dimension of the nanoparticle is from about 10 nm to about 900 nm. In embodiments, the average longest dimension of the nanoparticle is from about 10 nm to about 800 nm. In embodiments, the average longest dimension of the nanoparticle is from about 10 nm to about 700 nm. In embodiments, the average longest dimension of the nanoparticle is from about 100 nm to about 400 nm. In embodiments, the average longest dimension of the nanoparticle is from about 200 nm to about 500 nm. In embodiments, the average longest dimension of the nanoparticle is from about 300 nm to about 500 nm. In embodiments, the average longest dimension of the nanoparticle is from about 500 nm to about 1000 nm. In embodiments, the average longest dimension of the nanoparticle is from about 400 nm to about 800 nm.
  • the average longest dimension of the nanoparticle is from about 10 nm to about 600 nm. In embodiments, the average longest dimension of the nanoparticle is from about 10 nm to about 300 nm. In embodiments, the average longest dimension of the nanoparticle is from about 10 nm to about 100 nm. In embodiments, the average longest dimension of the nanoparticle is from about 10 nm to about 90 nm. In embodiments, the average longest dimension of the nanoparticle is from about 10 nm to about 80 nm. In embodiments, the average longest dimension of the nanoparticle is from about 10 nm to about 70 nm. In embodiments, the average longest dimension of the nanoparticle is from about 10 nm to about 60 nm.
  • the average longest dimension of the nanoparticle is from about 10 nm to about 50 nm. In embodiments, the average longest dimension of the nanoparticle is from about 25 nm to about 75 nm. In embodiments, the average longest dimension of the nanoparticle is from about 40 nm to about 60 nm. In embodiments, the average longest dimension of the nanoparticle is from about 45 nm to about 55 nm. In embodiments, the average longest dimension of the nanoparticle is about 51 nm.
  • the average longest dimension of the nanoparticle is from about 200 nm to about 250 nm. In embodiments, the average longest dimension of the nanoparticle is from about 400 nm to about 600 nm. In embodiments, the average longest dimension of the nanoparticle is from about 430 nm to about 530 nm.
  • the average longest dimension of the nanoparticle is from about 100 nm to about 400 nm. In embodiments, the average longest dimension of the nanoparticle is about 170 nm to 270 nm. In embodiments, the average longest dimension of the nanoparticle is about 10 nm, 15 nm, 20 nm, 25 nm, 30 nm, 35 nm, 40 nm, 45 nm, 50 nm, 55 nm, 60 nm, 65 nm, 70 nm, 75 nm, 80 nm, 85 nm, 90 nm, 95 nm, 100 nm, 105 nm, 110 nm, 115 nm, 120 nm, 125 nm, 130 nm, 135 nm, 140 nm, 145 nm, 150 nm, 155 nm, 160 nm, 165 nm, 170 nm, 175 nm, 180 nm, 185
  • the average longest dimension of the nanoparticle is from about 600 nm, 605 nm, 610 nm, 615 nm, 620 nm, 625 nm, 630 nm, 635 nm, 640 nm, 645 nm, 650 nm, 655 nm, 660 nm, 665 nm, 670 nm, 675 nm, 680 nm, 685 nm, 690 nm, 695 nm, 700 nm, 705 nm, 710 nm, 715 nm, 720 nm, 725 nm, 730 nm, 735 nm, 740 nm, 745 nm, 750 nm, 755 nm, 760 nm, 765 nm, 770 nm, 775 nm, 780 nm, 785 nm, 790 nm, 795 nm, 800
  • the average longest dimension of the nanoparticle is less than about 1000 nm. In embodiments, the average longest dimension of the nanoparticle is less than about 900 nm. In embodiments, the average longest dimension of the nanoparticle is less than about 800 nm. In embodiments, the average longest dimension of the nanoparticle is less than about 700 nm. In embodiments, the average longest dimension of the nanoparticle is less than about 600 nm. In embodiments, the average longest dimension of the nanoparticle is less than about 500 nm. In embodiments, the average longest dimension of the nanoparticle is less than about 400 nm. In embodiments, the average longest dimension of the nanoparticle is less than about 300 nm.
  • the average longest dimension of the nanoparticle is less than about 200 nm. In embodiments, the average longest dimension of the nanoparticle is less than about 100 nm. In embodiments, the average longest dimension of the nanoparticle is less than about 90 nm. In embodiments, the average longest dimension of the nanoparticle is less than about 80 nm. In embodiments, the average longest dimension of the nanoparticle is less than about 70 nm. In embodiments, the average longest dimension of the nanoparticle is less than about 60 nm. In embodiments, the average longest dimension of the nanoparticle is less than about 50 nm. In embodiments, the average longest dimension of the nanoparticle is less than about 40 nm.
  • the average longest dimension of the nanoparticle is less than about 30 nm. In embodiments, the average longest dimension of the nanoparticle is less than about 20 nm. In embodiments, the average longest dimension of the nanoparticle is less than about 10 nm.
  • the average longest dimension of the nanoparticle is less than about 10 nm, 15 nm, 20 nm, 25 nm, 30 nm, 35 nm, 40 nm, 45 nm, 50 nm, 55 nm, 60 nm, 65 nm, 70 nm, 75 nm, 80 nm, 85 nm, 90 nm, 95 nm, 100 nm, 105 nm, 110 nm, 115 nm, 120 nm, 125 nm, 130 nm, 135 nm, 140 nm, 145 nm, 150 nm, 155 nm, 160 nm, 165 nm, 170 nm, 175 nm, 180 nm, 185 nm, 190 nm, 195 nm, 200 nm, 205 nm, 210 nm, 215 nm, 220 nm, 225 nm,
  • the average longest dimension of the nanoparticle is less than about 600 nm, 605 nm, 610 nm, 615 nm, 620 nm, 625 nm, 630 nm, 635 nm, 640 nm, 645 nm, 650 nm, 655 nm, 660 nm, 665 nm, 670 nm, 675 nm, 680 nm, 685 nm, 690 nm, 695 nm, 700 nm, 705 nm, 710 nm, 715 nm, 720 nm, 725 nm, 730 nm, 735 nm, 740 nm, 745 nm, 750 nm, 755 nm, 760 nm, 765 nm, 770 nm, 775 nm, 780 nm, 785 nm, 790 nm, 795 nm,
  • the average longest dimension of the nanoparticle is less than 1000 nm. In embodiments, the average longest dimension of the nanoparticle is less than 900 nm. In embodiments, the average longest dimension of the nanoparticle is less than 800 nm. In embodiments, the average longest dimension of the nanoparticle is less than 700 nm. In embodiments, the average longest dimension of the nanoparticle is less than 600 nm. In embodiments, the average longest dimension of the nanoparticle is less than 500 nm. In embodiments, the average longest dimension of the nanoparticle is less than 400 nm. In embodiments, the average longest dimension of the nanoparticle is less than 300 nm. In embodiments, the average longest dimension of the nanoparticle is less than 200 nm.
  • the average longest dimension of the nanoparticle is less than 100 nm. In embodiments, the average longest dimension of the nanoparticle is less than 90 nm. In embodiments, the average longest dimension of the nanoparticle is less than 80 nm. In embodiments, the average longest dimension of the nanoparticle is less than 70 nm. In embodiments, the average longest dimension of the nanoparticle is less than 60 nm. In embodiments, the average longest dimension of the nanoparticle is less than 50 nm. In embodiments, the average longest dimension of the nanoparticle is less than 40 nm. In embodiments, the average longest dimension of the nanoparticle is less than 30 nm. In embodiments, the average longest dimension of the nanoparticle is less than 20 nm. In embodiments, the average longest dimension of the nanoparticle is less than 10 nm.
  • the average longest dimension of the nanoparticle is less than 10 nm, 15 nm, 20 nm, 25 nm, 30 nm, 35 nm, 40 nm, 45 nm, 50 nm, 55 nm, 60 nm, 65 nm, 70 nm, 75 nm, 80 nm, 85 nm, 90 nm, 95 nm, 100 nm, 105 nm, 110 nm, 115 nm, 120 nm, 125 nm, 130 nm, 135 nm, 140 nm, 145 nm, 150 nm, 155 nm, 160 nm, 165 nm, 170 nm, 175 nm, 180 nm, 185 nm, 190 nm, 195 nm, 200 nm, 205 nm, 210 nm, 215 nm, 220 nm, 225 nm, 230
  • the average longest dimension of the nanoparticle is less than 600 nm, 605 nm, 610 nm, 615 nm, 620 nm, 625 nm, 630 nm, 635 nm, 640 nm, 645 nm, 650 nm, 655 nm, 660 nm, 665 nm, 670 nm, 675 nm, 680 nm, 685 nm, 690 nm, 695 nm, 700 nm, 705 nm, 710 nm, 715 nm, 720 nm, 725 nm, 730 nm, 735 nm, 740 nm, 745 nm, 750 nm, 755 nm, 760 nm, 765 nm, 770 nm, 775 nm, 780 nm, 785 nm, 790 nm, 795 nm, 800
  • the nanoparticle further includes a detectable compound.
  • the unmodified silica nanoparticle includes a detectable compound.
  • the detectable compound is a radioisotope, fluorophore, electron-dense reagent, enzyme, biotin, paramagnetic agent, or magnetic agent.
  • the detectable compound is a radioisotope.
  • the detectable compound is a fluorophore.
  • the detectable compound includes cyanine, heptamethine, xanthene, rhodamine, fluorescein, boron-dipyrromethene, boron dipyridyl, naphthalene, coumarin, acridine, acridinium, tetrapyrrole, tetraphenylethene, oxazine, pyrene, oxadiazole, subphthalocyanine, carbopyrinin, benzopyrinium, or phthalocyanine.
  • the fluorophore is indocyanine green or a coumarin dye.
  • the detectable agent is indocyanine green.
  • the fluorophore is an FDA approved dye for clinical use. In embodiments, the fluorophore has a low toxicity profile.
  • common fluorescent proteins or non-protein organic fluorophores may be examples of a detectable compound.
  • a cell including a nanoparticle e.g., a silica nanoparticle described herein.
  • the cell is a tumor tropic cell, macrophage, stem cell (e.g., neural, mesenchymal), or T-cell.
  • the cell is neural stem cell, a mesenchymal stem cell, a mesenchymal stromal cell, a hematopoetic stem cell, T-lymphocyte, a macrophage, or a liver stem cell.
  • the cell is a neural stem cell.
  • the cell is genetically modified.
  • the cell is a genetically modified stem cell.
  • the cell is a genetically modified neural stem cell.
  • the neural stem cell is a human HB1.F3 stem cell.
  • the nanoparticle is within the cell.
  • the nanoparticle is incorporated within the cell via the enhanced permeability and retention (EPR) effect.
  • EPR enhanced permeability and retention
  • a nanoparticle-cell construct including a nanoparticle covalently attached to a protein (e.g., a cell-surface protein) through a covalent linker.
  • the protein is attached to cell and is a cell surface protein.
  • the protein includes a sulfur-containing amino acid.
  • the protein includes methionine, cysteine, homocysteine, or taurine.
  • the protein includes a sulfhydryl moiety.
  • the nanoparticle is a silica nanoparticle.
  • the nanoparticle is a silica nanoparticle which further comprises a platinum anti-cancer agent.
  • the nanoparticle is an inorganic nanoparticle.
  • the nanoparticle is a silica nanoparticle.
  • the inorganic nanoparticle may be a metal nanoparticle.
  • the metal of the metal nanoparticle may be in the form of a metal oxide and the metal nanoparticle a metal oxide nanoparticle.
  • the metal oxide nanoparticle may be titanium oxide or zirconium oxide.
  • the nanoparticle is a gold nanoparticle.
  • the nanoparticle is an iron nanoparticle.
  • the nanoparticle is an iron oxide nanoparticle.
  • the protein is a cell surface protein.
  • a cell surface protein refers to a protein at the surface of a protein.
  • the cell surface protein is a transmembrane protein.
  • the protein is in contact with the extracellular matrix (e.g., extracellular matrix associated with a cancer cell or in contact with a cancer cell).
  • the protein is in contact with a tumor.
  • the tumor includes stromal cells, immune cells, proteins, and extracellular matrix generated by those cells.
  • immune cells, stromal cells, proteins associate with the immune cells, proteins associated with the stromal cells, and the extracellular matrix generated from immune cells and stromal cells forms part of a tumor.
  • the covalent linker has the formula: -L 2 -X 1 -L 1 -X 2 -L 3 - (Ia) or -L 2 -X 2 -L 3 - (Ib).
  • X 1 and X 2 are independently a bioconjugate linker or a bond, wherein one of X 1 or X 2 is a bioconjugate linker.
  • L is independently a polymeric linker.
  • L 2 is independently a bond, —NR 1a —, —O—, —S—, —C(O)—, —C(O)O—, —S(O)—, —S(O) 2 —, —NR 1a C(O)—, —C(O)NR 1b —, —C(O)(CH 2 ) z1 —, —NR 1a C(O)O—, —NR 1a C(O)NR 1b —, substituted or unsubstituted alkylene, substituted or unsubstituted heteroalkylene, substituted or unsubstituted cycloalkylene, substituted or unsubstituted heterocycloalkylene, substituted or unsubstituted arylene, or substituted or unsubstituted heteroarylene.
  • L 3 is independently a bond, —NR 2a —, —O—, —S—, —C(O)—, —C(O)O—, —S(O)—, —S(O) 2 —, —NR 2a C(O)—, —C(O)NR 2b —, —C(O)(CH 2 ) z2 —, —NR 2a C(O)O—, —NR 2a C(O)NR 2b —, substituted or unsubstituted alkylene, substituted or unsubstituted heteroalkylene, substituted or unsubstituted cycloalkylene, substituted or unsubstituted heterocycloalkylene, substituted or unsubstituted arylene, or substituted or unsubstituted heteroarylene.
  • R 1a , R 2a , R 1b , and R 2b are independently hydrogen, halogen, —CF 3 , —CN, —OH, —NH 2 , —COOH, —CONH 2 , —NO 2 , —SH, —SO 3 H, —SO 4 H, —SO 2 NH 2 , —NHNH 2 , —ONH 2 , —NHC ⁇ (O)NHNH 2 , —NHC ⁇ (O)NH 2 , —NHSO 2 H, —NHC ⁇ (O)H, —NHC(O)OH, —NHOH, —OCF 3 , —OCHF 2 , substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstit
  • R 1a , R 2a , R 1b , and R 2b are independently hydrogen, halogen, —CF 3 , —CN, —OH, —COOH, —CONH 2 , substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl; the symbols z1 and z2 are independently an integer from 1 to 10.
  • X 2 is a bioconjugate linker.
  • the polymeric linker does not include poly(lactate)-poly(ethylene glycol) copolymer, poly( ⁇ -amino ester), poly(lactate), poly(ethylene glycol)-dimethacrylate, or methyl ether poly(ethylene glycol)-poly(3-amino ester) copolymer.
  • X 1 or X 2 independently do not include biotin.
  • -L 2 -X 1 -L 1 -X 2 -L 3 - or -L 2 -X 2 -L 3 - does not include biotin.
  • -L 2 -X 1 -L 1 -X 2 -L 3 - and -L 2 -X 2 -L 3 - does not include biotin.
  • the silica nanoparticle does not include biotin.
  • L 2 has the formula -L 2A -L 2B -.
  • L 2A and L 2B are independently a bond, —NR 1a —, —O—, —S—, —C(O)—, —C(O)O—, —S(O)—, —S(O) 2 —, —NR 1a C(O)—, —C(O)NR 1b —, —C(O)(CH 2 ) z1 —, —NR 1a C(O)O—, —NR 1a C(O)NR 1b —, substituted or unsubstituted alkylene, substituted or unsubstituted heteroalkylene, substituted or unsubstituted cycloalkylene, substituted or unsubstituted heterocycloalkylene, substituted or unsubstituted arylene, or substituted or unsubstituted heteroarylene.
  • L 2A is a substituted (e.g., substituted with a substituent group, a size-limited substituent group, or lower substituent group) or unsubstituted alkylene, substituted (e.g., substituted with a substituent group, a size-limited substituent group, or lower substituent group) or unsubstituted heteroalkylene, substituted (e.g., substituted with a substituent group, a size-limited substituent group, or lower substituent group) or unsubstituted cycloalkylene, substituted (e.g., substituted with a substituent group, a size-limited substituent group, or lower substituent group) or unsubstituted heterocycloalkylene, substituted (e.g., substituted with a substituent group, a size-limited substituent group, or lower substituent group) or unsubstituted arylene, or substituted (e.g., substituted with a substituent group, a size-limited substituent group
  • L 2B is a substituted (e.g., substituted with a substituent group, a size-limited substituent group, or lower substituent group) or unsubstituted alkylene, substituted (e.g., substituted with a substituent group, a size-limited substituent group, or lower substituent group) or unsubstituted heteroalkylene, substituted (e.g., substituted with a substituent group, a size-limited substituent group, or lower substituent group) or unsubstituted cycloalkylene, substituted (e.g., substituted with a substituent group, a size-limited substituent group, or lower substituent group) or unsubstituted heterocycloalkylene, substituted (e.g., substituted with a substituent group, a size-limited substituent group, or lower substituent group) or unsubstituted arylene, or substituted (e.g., substituted with a substituent group, a size-limited substituent group
  • L 2A and L 2B are independently an unsubstituted alkylene, unsubstituted heteroalkylene, unsubstituted cycloalkylene, unsubstituted heterocycloalkylene, unsubstituted arylene, or unsubstituted heteroarylene.
  • the nanoparticle is further covalently attached to one or more nanoparticle substituents.
  • the nanoparticle substituent includes a polymeric moiety.
  • the polymeric moiety is a polyethylene glycol moiety.
  • the nanoparticle substituent is: -L 2 -X 1 —R 3 (i); -L 2 -X 1 -L 1 -X 3 (ii); or -L 2 -X 3 (iii).
  • L 1 , L 2 , X 1 , L 1 and X 3 are as defined below and are optionally different.
  • R 3 is independently a polymeric moiety.
  • X 3 is independently a bioconjugate reactive group. In embodiments, one or more of L 1 , L 2 , X 1 , L 1 and X 3 are the same.
  • L 1 is a linear polymeric linker. In embodiments, L 1 is a branched polymeric linker. In embodiments, a nanoparticle includes multiple, optionally different, L 1 linkers and each L 1 linker is independently a linear or branched polymeric linker. In embodiments, L 1 is branched with 3 to 10 branches. In embodiments, when L 1 is branched, there is one bioconjugate reactive group. In embodiments, when L 1 is branched there is a plurality of bioconjugate reactive groups.
  • L 1 is polyethylene glycol. In embodiments, L 1 is divalent -PEG 400 -SH. In embodiments, L 1 is divalent -PEG 1000 -SH. In embodiments, L 1 is divalent -PEG 2000 -SH. In embodiments, L 1 is divalent -PEG 5000 -SH. It will be understood that the immediately preceding divalent PEG-SH groups may be bonded to a separate moiety through the terminal thiol group where the bond between sulfur and hydrogen is replaced with a bond between sulfur and another moiety. In embodiments, L 1 is divalent -TFP-(PEG 11 ) 3 .
  • TFP-PEG groups may be bonded to a separate moiety through the tetrafluorophenyl (TFP) ester group wherein the bond is between the tetrafluorophenyl ester and another moiety.
  • L 1 is divalent NHS-(PEG 24 ) 3 .
  • NSH-PEG groups may be bonded to a separate moiety through the N-hydroxysuccinimide group where the bond is between N-hydroxysuccinimide and another moiety.
  • L 1 is polyethylene glycol with an average molecular weight of about 400 g/mol, 484 g/mol, 1000 g/mol, 1450 g/mol, 1500 g/mol, 2000 g/mol, or 5000 g/mol. In embodiments, L 1 is polyethylene glycol with an average molecular weight of about 400 g/mol, 484 g/mol, 1000 g/mol, 1450 g/mol, 1500 g/mol, 2000 g/mol, or 5000 g/mol within +/ ⁇ 10, 20, 30, 40, or 50 of the average molecular weight.
  • L 1 is polyethylene glycol with an average molecular weight of about 400 g/mol. In embodiments, L 1 is polyethylene glycol with an average molecular weight of about 484 g/mol. In embodiments, L 1 is polyethylene glycol with an average molecular weight of about 484 g/mol per arm. In embodiments, L 1 is polyethylene glycol with an average molecular weight of about 1000 g/mol. In embodiments, L 1 is polyethylene glycol with an average molecular weight of about 1450 g/mol. In embodiments, L 1 is polyethylene glycol with an average molecular weight of about 1500 g/mol. In embodiments, L 1 is polyethylene glycol with an average molecular weight of about 2000 g/mol. In embodiments, L 1 is polyethylene glycol with an average molecular weight of about 5000 g/mol.
  • L 1 is a polymeric linker further including substituted or unsubstituted alkylene, substituted or unsubstituted heteroalkylene, substituted or unsubstituted cycloalkylene, substituted or unsubstituted heterocycloalkylene, substituted or unsubstituted arylene, or substituted or unsubstituted heteroarylene.
  • L 1 is a polymeric linker further comprising unsubstituted alkylene, unsubstituted heteroalkylene, unsubstituted cycloalkylene, unsubstituted heterocycloalkylene, unsubstituted arylene, or unsubstituted heteroarylene.
  • L 1 is a polymeric linker further including unsubstituted alkylene, unsubstituted heteroalkylene, unsubstituted cycloalkylene, unsubstituted heterocycloalkylene, unsubstituted arylene, or unsubstituted heteroarylene.
  • L 2 is independently a bond, —NR 1a —, —O—, —S—, —C(O)—, —C(O)O—, —S(O)—, —S(O) 2 —, —NR 1a C(O)—, —C(O)NR 1b —, —C(O)(CH 2 ) z1 —, —NR 1a C(O)O—, —NR 1a C(O)NR 1b —, substituted or unsubstituted alkylene (e.g.
  • arylene e.g. C 6 -C 10 arylene or C 6 arylene
  • heteroarylene e.g. 5 to 10 membered heteroarylene, 5 to 9 membered heteroarylene, or 5 to 6 membered heteroarylene.
  • L 2 has the formula:
  • L 2 has the formula:
  • L 2 has the formula:
  • L 2 has the formula:
  • L 2 has the formula:
  • L 2 has the formula:
  • L 2 has the formula:
  • L 2 is independently a bond, —NR 1a —, —O—, —S—, —C(O)—, —C(O)O—, —S(O)—, —S(O) 2 —, —NR 1a C(O)—, —C(O)NR 1b —, —C(O)(CH 2 ) z1 —, —NR 1a C(O)O—, —NR 1a C(O)NR 1b —, R 4 -substituted or unsubstituted alkylene (e.g.
  • R 4 -substituted or unsubstituted heteroalkylene e.g. 2 to 10 membered heteroalkylene, 2 to 8 membered heteroalkylene, 4 to 8 membered heteroalkylene, 2 to 6 membered heteroalkylene, or 2 to 4 membered heteroalkylene
  • R 4 -substituted or unsubstituted cycloalkylene e.g.
  • R 4 -substituted or unsubstituted heterocycloalkylene e.g. 3 to 8 membered heterocycloalkylene, 4 to 8 membered heterocycloalkylene, or 5 to 6 membered heterocycloalkylene
  • R 4 -substituted or unsubstituted arylene e.g. C 6 -C 10 arylene or C 6 arylene
  • R 4 -substituted or unsubstituted heteroarylene e.g.
  • L 2 is independently a bond, —NR 1a —, —O—, —S—, —C(O)—, —C(O)O—, —S(O)—, —S(O) 2 —, —NR 1a C(O)—, —C(O)NR 1b —, —C(O)(CH 2 ) z1 —, —NR 1a C(O)O—, —NR 1a C(O)NR 1b —, Unsubstituted alkylene (e.g.
  • arylene e.g. C 6 -C 10 arylene or C 6 arylene
  • heteroarylene e.g. 5 to 10 membered heteroarylene, 5 to 9 membered heteroarylene, or 5 to 6 membered heteroarylene.
  • L 2 is independently a bond, —NR 1a —, —O—, —S—, —C(O)—, —C(O)O—, —S(O)—, —S(O) 2 —, —NR 1a C(O)—, —C(O)NR 1b —, —C(O)(CH 2 ) z1 —, —NR 1a C(O)O—, —NR 1a C(O)NR 1b —, unsubstituted alkylene (e.g. C 1 -C 8 alkylene, C 1 -C 6 alkylene, or C 1 -C 4 alkylene), unsubstituted heteroalkylene (e.g.
  • alkylene e.g. C 1 -C 8 alkylene, C 1 -C 6 alkylene, or C 1 -C 4 alkylene
  • heteroalkylene e.g.
  • cycloalkylene
  • R 4 is independently oxo
  • halogen —CF 3 , —CN, —OH, —NH 2 , —COOH, —CONH 2 , —NO 2 , —SH, —SO 3 H, —SO 4 H, —SO 2 NH 2 , —NHNH 2 , —ONH 2 , —NHC ⁇ (O)NHNH 2 , —NHC ⁇ (O) NH 2 , —NHSO 2 H, —NHC ⁇ (O)H, —NHC(O)—OH, —NHOH, —OCF 3 , —OCHF 2 , R 5 -substituted or unsubstituted alkyl (e.g.
  • R 5 -substituted or unsubstituted aryl e.g. C 6 -C 10 aryl or C 6 aryl
  • R 5 -substituted or unsubstituted heteroaryl e.g. 5 to 10 membered heteroaryl, 5 to 9 membered heteroaryl, or 5 to 6 membered heteroaryl.
  • L 3 is independently a bond, —NR 2a —, —O—, —S—, —C(O)—, —C(O)O—, —S(O)—, —S(O) 2 —, —NR 2a C(O)—, —C(O)NR 2b —, —C(O)(CH 2 ) z2 —, —NR 2a C(O)O—, —NR 2a C(O)NR 2b —, substituted or unsubstituted alkylene (e.g.
  • arylene e.g. C 6 -C 10 arylene or C 6 arylene
  • heteroarylene e.g. 5 to 10 membered heteroarylene, 5 to 9 membered heteroarylene, or 5 to 6 membered heteroarylene.
  • L 3 is independently a bond, —NR 2a —, —O—, —S—, —C(O)—, —C(O)O—, —S(O)—, —S(O) 2 —, —NR 2a C(O)—, —C(O)NR 2b —, —C(O)(CH 2 ) z2 —, —NR 2a C(O)O—, —NR 2a C(O)NR 2b —, R 6 -substituted or unsubstituted alkylene (e.g.
  • R 6 -substituted or unsubstituted heteroalkylene e.g. 2 to 10 membered heteroalkylene, 2 to 8 membered heteroalkylene, 4 to 8 membered heteroalkylene, 2 to 6 membered heteroalkylene, or 2 to 4 membered heteroalkylene
  • R 6 -substituted or unsubstituted cycloalkylene e.g.
  • R 6 -substituted or unsubstituted heterocycloalkylene e.g. 3 to 8 membered heterocycloalkylene, 4 to 8 membered heterocycloalkylene, or 5 to 6 membered heterocycloalkylene
  • R 6 -substituted or unsubstituted arylene e.g. C 6 -C 10 arylene or C 6 arylene
  • R 6 -substituted or unsubstituted heteroarylene e.g. 5 to 10 membered heteroarylene, 5 to 9 membered heteroarylene, or 5 to 6 membered heteroarylene.
  • R 6 is independently oxo
  • halogen —CF 3 , —CN, —OH, —NH 2 , —COOH, —CONH 2 , —NO 2 , —SH, —SO 3 H, —SO 4 H, —SO 2 NH 2 , —NHNH 2 , —ONH 2 , —NHC ⁇ (O)NHNH 2 , —NHC ⁇ (O) NH 2 , —NHSO 2 H, —NHC ⁇ (O)H, —NHC(O)—OH, —NHOH, —OCF 3 , —OCHF 2 , R 7 -substituted or unsubstituted alkyl (e.g.
  • R 7 -substituted or unsubstituted aryl e.g. C 6 -C 10 aryl or C 6 aryl
  • R 7 -substituted or unsubstituted heteroaryl e.g. 5 to 10 membered heteroaryl, 5 to 9 membered heteroaryl, or 5 to 6 membered heteroaryl.
  • R 5 and R 7 are independently oxo
  • halogen —F, —Cl, —Br, —I, —CF 3 , —CCl 3 , —CN, —OH, —NH 2 , —COOH, —CONH 2 , —NO 2 , —SH, —SO 3 H, —SO 4 H, —SO 2 NH 2 , —NHNH 2 , —ONH 2 , —NHC ⁇ (O)NHNH 2 , —NHC ⁇ (O) NH 2 , —NHSO 2 H, —NHC ⁇ (O)H, —NHC(O)—OH, —NHOH, —OCF 3 , —OCHF 2 , unsubstituted alkyl (e.g.
  • aryl e.g. C 6 -C 10 aryl or C 6 aryl
  • heteroaryl e.g. 5 to 10 membered heteroaryl, 5 to 9 membered heteroaryl, or 5 to 6 membered heteroaryl.
  • R 1a , R 2a , R 1b , and R 2b are independently hydrogen, halogen, —CF 3 , —CN, —OH, —NH 2 , —COOH, —CONH 2 , —NO 2 , —SH, —SO 3 H, —SO 4 H, —SO 2 NH 2 , —NHNH 2 , —ONH 2 , —NHC ⁇ (O)NHNH 2 , —NHC ⁇ (O)NH 2 , —NHSO 2 H, —NHC ⁇ (O)H, —NHC(O)OH, —NHOH, —OCF 3 , —OCHF 2 , substituted or unsubstituted alkyl (e.g.
  • aryl e.g. C 6 -C 10 aryl or C 6 aryl
  • heteroaryl e.g. 5 to 10 membered heteroaryl, 5 to 9 membered heteroaryl, or 5 to 6 membered heteroaryl.
  • R 1a , R 2a , R 1b , and R 2b are independently hydrogen, halogen, —CF 3 , —CN, —OH, —COOH, —CONH 2 , substituted or unsubstituted alkyl (e.g. C 1 -C 8 alkyl, C 1 -C 6 alkyl, or C 1 -C 4 alkyl), substituted or unsubstituted heteroalkyl (e.g.
  • substituted or unsubstituted cycloalkyl e.g. C 3 -C 8 cycloalkyl, C 4 -C 8 cycloalkyl, or C 5 -C 6 cycloalkyl
  • substituted or unsubstituted heterocycloalkyl e.g.
  • aryl e.g. C 6 -C 10 aryl or C 6 aryl
  • heteroaryl e.g. 5 to 10 membered heteroaryl, 5 to 9 membered heteroaryl, or 5 to 6 membered heteroaryl.
  • R 1a is independently hydrogen
  • halogen —CF 3 , —CN, —OH, —NH 2 , —COOH, —CONH 2 , —NO 2 , —SH, —SO 3 H, —SO 4 H, —SO 2 NH 2 , —NHNH 2 , —ONH 2 , —NHC ⁇ (O)NHNH 2 , —NHC ⁇ (O)NH 2 , —NHSO 2 H, —NHC ⁇ (O)H, —NHC(O)OH, —NHOH, —OCF 3 , —OCHF 2 , R 8 -substituted or unsubstituted alkyl (e.g.
  • R 8 -substituted or unsubstituted heteroalkyl e.g. 2 to 10 membered heteroalkyl, 2 to 8 membered heteroalkyl, 4 to 8 membered heteroalkyl, 2 to 6 membered heteroalkyl, or 2 to 4 membered heteroalkyl
  • R 8 -substituted or unsubstituted cycloalkyl e.g.
  • R 8 -substituted or unsubstituted heterocycloalkyl e.g. 3 to 8 membered heterocycloalkyl, 4 to 8 membered heterocycloalkyl, or 5 to 6 membered heterocycloalkyl
  • R 8 -substituted or unsubstituted aryl e.g. C 6 -C 10 aryl or C 6 aryl
  • R 8 -substituted or unsubstituted heteroaryl e.g.
  • R 1a is independently hydrogen, halogen, —CF 3 , —CN, —OH, —NH 2 , —COOH, —CONH 2 , —NO 2 , —SH, —SO 3 H, —SO 4 H, —SO 2 NH 2 , —NHNH 2 , —ONH 2 , —NHC ⁇ (O)NHNH 2 , —NHC ⁇ (O)NH 2 , —NHSO 2 H, —NHC ⁇ (O)H, —NHC(O)OH, —NHOH, —OCF 3 , —OCHF 2 , unsubstituted alkyl (e.g.
  • aryl e.g. C 6 -C 10 aryl or C 6 aryl
  • heteroaryl e.g. 5 to 10 membered heteroaryl, 5 to 9 membered heteroaryl, or 5 to 6 membered heteroaryl.
  • R 8 is independently hydrogen
  • halogen —CF 3 , —CN, —OH, —NH 2 , —COOH, —CONH 2 , —NO 2 , —SH, —SO 3 H, —SO 4 H, —SO 2 NH 2 , —NHNH 2 , —ONH 2 , —NHC ⁇ (O)NHNH 2 , —NHC ⁇ (O)NH 2 , —NHSO 2 H, —NHC ⁇ (O)H, —NHC(O)OH, —NHOH, —OCF 3 , —OCHF 2 , R 9 -substituted or unsubstituted alkyl (e.g.
  • R 9 -substituted or unsubstituted heteroalkyl e.g. 2 to 10 membered heteroalkyl, 2 to 8 membered heteroalkyl, 4 to 8 membered heteroalkyl, 2 to 6 membered heteroalkyl, or 2 to 4 membered heteroalkyl
  • R 9 -substituted or unsubstituted cycloalkyl e.g.
  • R 9 -substituted or unsubstituted heterocycloalkyl e.g. 3 to 8 membered heterocycloalkyl, 4 to 8 membered heterocycloalkyl, or 5 to 6 membered heterocycloalkyl
  • R 9 -substituted or unsubstituted aryl e.g. C 6 -C 10 aryl or C 6 aryl
  • R 9 -substituted or unsubstituted heteroaryl e.g. 5 to 10 membered heteroaryl, 5 to 9 membered heteroaryl, or 5 to 6 membered heteroaryl.
  • R 1b is independently hydrogen
  • halogen —CF 3 , —CN, —OH, —NH 2 , —COOH, —CONH 2 , —NO 2 , —SH, —SO 3 H, —SO 4 H, —SO 2 NH 2 , —NHNH 2 , —ONH 2 , —NHC ⁇ (O)NHNH 2 , —NHC ⁇ (O)NH 2 , —NHSO 2 H, —NHC ⁇ (O)H, —NHC(O)OH, —NHOH, —OCF 3 , —OCHF 2 , R 10 -substituted or unsubstituted alkyl (e.g.
  • R 10 -substituted or unsubstituted heteroalkyl e.g. 2 to 10 membered heteroalkyl, 2 to 8 membered heteroalkyl, 4 to 8 membered heteroalkyl, 2 to 6 membered heteroalkyl, or 2 to 4 membered heteroalkyl
  • R 10 -substituted or unsubstituted cycloalkyl e.g.
  • R 10 -substituted or unsubstituted heterocycloalkyl e.g. 3 to 8 membered heterocycloalkyl, 4 to 8 membered heterocycloalkyl, or 5 to 6 membered heterocycloalkyl
  • R 10 -substituted or unsubstituted aryl e.g. C 6 -C 10 aryl or C 6 aryl
  • R 10 -substituted or unsubstituted heteroaryl e.g.
  • R 1b is independently hydrogen, halogen, —CF 3 , —CN, —OH, —NH 2 , —COOH, —CONH 2 , —NO 2 , —SH, —SO 3 H, —SO 4 H, —SO 2 NH 2 , —NHNH 2 , —ONH 2 , —NHC ⁇ (O)NHNH 2 , —NHC ⁇ (O)NH 2 , —NHSO 2 H, —NHC ⁇ (O)H, —NHC(O)OH, —NHOH, —OCF 3 , —OCHF 2 , unsubstituted alkyl (e.g.
  • aryl e.g. C 6 -C 10 aryl or C 6 aryl
  • heteroaryl e.g. 5 to 10 membered heteroaryl, 5 to 9 membered heteroaryl, or 5 to 6 membered heteroaryl.
  • R 10 is independently hydrogen
  • halogen —CF 3 , —CN, —OH, —NH 2 , —COOH, —CONH 2 , —NO 2 , —SH, —SO 3 H, —SO 4 H, —SO 2 NH 2 , —NHNH 2 , —ONH 2 , —NHC ⁇ (O)NHNH 2 , —NHC ⁇ (O)NH 2 , —NHSO 2 H, —NHC ⁇ (O)H, —NHC(O)OH, —NHOH, —OCF 3 , —OCHF 2 , R 11 -substituted or unsubstituted alkyl (e.g.
  • R 11 -substituted or unsubstituted heteroalkyl e.g. 2 to 10 membered heteroalkyl, 2 to 8 membered heteroalkyl, 4 to 8 membered heteroalkyl, 2 to 6 membered heteroalkyl, or 2 to 4 membered heteroalkyl
  • R 11 -substituted or unsubstituted cycloalkyl e.g.
  • R 11 -substituted or unsubstituted heterocycloalkyl e.g. 3 to 8 membered heterocycloalkyl, 4 to 8 membered heterocycloalkyl, or 5 to 6 membered heterocycloalkyl
  • R 11 -substituted or unsubstituted aryl e.g. C 6 -C 10 aryl or C 6 aryl
  • R 11 -substituted or unsubstituted heteroaryl e.g. 5 to 10 membered heteroaryl, 5 to 9 membered heteroaryl, or 5 to 6 membered heteroaryl.
  • R 2a is independently hydrogen
  • halogen —CF 3 , —CN, —OH, —NH 2 , —COOH, —CONH 2 , —NO 2 , —SH, —SO 3 H, —SO 4 H, —SO 2 NH 2 , —NHNH 2 , —ONH 2 , —NHC ⁇ (O)NHNH 2 , —NHC ⁇ (O)NH 2 , —NHSO 2 H, —NHC ⁇ (O)H, —NHC(O)OH, —NHOH, —OCF 3 , —OCHF 2 R 12 -substituted or unsubstituted alkyl (e.g.
  • R 12 -substituted or unsubstituted heteroalkyl e.g. 2 to 10 membered heteroalkyl, 2 to 8 membered heteroalkyl, 4 to 8 membered heteroalkyl, 2 to 6 membered heteroalkyl, or 2 to 4 membered heteroalkyl
  • R 12 -substituted or unsubstituted cycloalkyl e.g.
  • R 12 -substituted or unsubstituted heterocycloalkyl e.g. 3 to 8 membered heterocycloalkyl, 4 to 8 membered heterocycloalkyl, or 5 to 6 membered heterocycloalkyl
  • R 12 -substituted or unsubstituted aryl e.g. C 6 -C 10 aryl or C 6 aryl
  • R 12 -substituted or unsubstituted heteroaryl e.g.
  • R 2a is independently hydrogen, halogen, —CF 3 , —CN, —OH, —NH 2 , —COOH, —CONH 2 , —NO 2 , —SH, —SO 3 H, —SO 4 H, —SO 2 NH 2 , —NHNH 2 , —ONH 2 , —NHC ⁇ (O)NHNH 2 , —NHC ⁇ (O)NH 2 , —NHSO 2 H, —NHC ⁇ (O)H, —NHC(O)OH, —NHOH, —OCF 3 , —OCHF 2 , unsubstituted alkyl (e.g.
  • aryl e.g. C 6 -C 10 aryl or C 6 aryl
  • heteroaryl e.g. 5 to 10 membered heteroaryl, 5 to 9 membered heteroaryl, or 5 to 6 membered heteroaryl.
  • R 12 is independently oxo
  • halogen —CF 3 , —CN, —OH, —NH 2 , —COOH, —CONH 2 , —NO 2 , —SH, —SO 3 H, —SO 4 H, —SO 2 NH 2 , —NHNH 2 , —ONH 2 , —NHC ⁇ (O)NHNH 2 , —NHC ⁇ (O)NH 2 , —NHSO 2 H, —NHC ⁇ (O)H, —NHC(O)OH, —NHOH, —OCF 3 , —OCHF 2 , R 1 -substituted or unsubstituted alkyl (e.g.
  • R 13 -substituted or unsubstituted heteroalkyl e.g. 2 to 10 membered heteroalkyl, 2 to 8 membered heteroalkyl, 4 to 8 membered heteroalkyl, 2 to 6 membered heteroalkyl, or 2 to 4 membered heteroalkyl
  • R 13 -substituted or unsubstituted cycloalkyl e.g.
  • R 13 -substituted or unsubstituted heterocycloalkyl e.g. 3 to 8 membered heterocycloalkyl, 4 to 8 membered heterocycloalkyl, or 5 to 6 membered heterocycloalkyl
  • R 13 -substituted or unsubstituted aryl e.g. C 6 -C 10 aryl or C 6 aryl
  • R 13 -substituted or unsubstituted heteroaryl e.g. 5 to 10 membered heteroaryl, 5 to 9 membered heteroaryl, or 5 to 6 membered heteroaryl.
  • R 2b is independently hydrogen
  • halogen —CF 3 , —CN, —OH, —NH 2 , —COOH, —CONH 2 , —NO 2 , —SH, —SO 3 H, —SO 4 H, —SO 2 NH 2 , —NHNH 2 , —ONH 2 , —NHC ⁇ (O)NHNH 2 , —NHC ⁇ (O)NH 2 , —NHSO 2 H, —NHC ⁇ (O)H, —NHC(O)OH, —NHOH, —OCF 3 , —OCHF 2 R 14 -substituted or unsubstituted alkyl (e.g.
  • R 14 -substituted or unsubstituted heteroalkyl e.g. 2 to 10 membered heteroalkyl, 2 to 8 membered heteroalkyl, 4 to 8 membered heteroalkyl, 2 to 6 membered heteroalkyl, or 2 to 4 membered heteroalkyl
  • R 14 -substituted or unsubstituted cycloalkyl e.g.
  • R 14 -substituted or unsubstituted heterocycloalkyl e.g. 3 to 8 membered heterocycloalkyl, 4 to 8 membered heterocycloalkyl, or 5 to 6 membered heterocycloalkyl
  • R 14 -substituted or unsubstituted aryl e.g. C 6 -C 10 aryl or C 6 aryl
  • R 14 -substituted or unsubstituted heteroaryl e.g.
  • R 2b is independently hydrogen, halogen, —CF 3 , —CN, —OH, —NH 2 , —COOH, —CONH 2 , —NO 2 , —SH, —SO 3 H, —SO 4 H, —SO 2 NH 2 , —NHNH 2 , —ONH 2 , —NHC ⁇ (O)NHNH 2 , —NHC ⁇ (O)NH 2 , —NHSO 2 H, —NHC ⁇ (O)H, —NHC(O)OH, —NHOH, —OCF 3 , —OCHF 2 , unsubstituted alkyl (e.g.
  • aryl e.g. C 6 -C 10 aryl or C 6 aryl
  • heteroaryl e.g. 5 to 10 membered heteroaryl, 5 to 9 membered heteroaryl, or 5 to 6 membered heteroaryl.
  • R 14 is independently oxo
  • halogen —CF 3 , —CN, —OH, —NH 2 , —COOH, —CONH 2 , —NO 2 , —SH, —SO 3 H, —SO 4 H, —SO 2 NH 2 , —NHNH 2 , —ONH 2 , —NHC ⁇ (O)NHNH 2 , —NHC ⁇ (O)NH 2 , —NHSO 2 H, —NHC ⁇ (O)H, —NHC(O)OH, —NHOH, —OCF 3 , —OCHF 2 , R 15 -substituted or unsubstituted alkyl (e.g.
  • R 15 -substituted or unsubstituted heteroalkyl e.g. 2 to 10 membered heteroalkyl, 2 to 8 membered heteroalkyl, 4 to 8 membered heteroalkyl, 2 to 6 membered heteroalkyl, or 2 to 4 membered heteroalkyl
  • R 15 -substituted or unsubstituted cycloalkyl e.g.
  • R 15 -substituted or unsubstituted heterocycloalkyl e.g. 3 to 8 membered heterocycloalkyl, 4 to 8 membered heterocycloalkyl, or 5 to 6 membered heterocycloalkyl
  • R 15 -substituted or unsubstituted aryl e.g. C 6 -C 10 aryl or C 6 aryl
  • R 15 -substituted or unsubstituted heteroaryl e.g. 5 to 10 membered heteroaryl, 5 to 9 membered heteroaryl, or 5 to 6 membered heteroaryl.
  • R 9 , R 11 , R 13 , R 15 are independently oxo, halogen, —F, —Cl, —Br, —I, —CF 3 , —CCl 3 , —CN, —OH, —NH 2 , —COOH, —CONH 2 , —NO 2 , —SH, —SO 3 H, —SO 4 H, —SO 2 NH 2 , —NHNH 2 , —ONH 2 , —NHC ⁇ (O)NHNH 2 , —NHC ⁇ (O) NH 2 , —NHSO 2 H, —NHC ⁇ (O)H, —NHC(O)—OH, —NHOH, —OCF 3 , —OCHF 2 , unsubstituted alkyl (e.g.
  • aryl e.g. C 6 -C 10 aryl or C 6 aryl
  • heteroaryl e.g. 5 to 10 membered heteroaryl, 5 to 9 membered heteroaryl, or 5 to 6 membered heteroaryl.
  • R 3 is monovalent polyethylene glycol (PEG). In embodiments, R 3 is monovalent PEG 400 -SH. In embodiments, R 3 is monovalent PEG 1000 -SH. In embodiments, R 3 is monovalent PEG 2000 -SH. In embodiments, R 3 is monovalent PEG 5000 -SH. It will be understood that the immediately preceding divalent PEG-SH groups may be bonded to a separate moiety through the terminal thiol group where the bond between sulfur and hydrogen is replaced with a bond between sulfur and another moiety. In embodiments, R 3 is monovalent TFP-(PEG 11 ) 3 .
  • TFP-PEG groups may be bonded to a separate moiety through the tetrafluorophenyl (TFP) ester group where the is between the tetrafluorophenyl ester and another moiety.
  • R 3 is monovalent NHS-(PEG 24 ) 3 .
  • NSH-PEG groups may be bonded to a separate moiety through the N-hydroxysuccinimide group where the bond is between N-hydroxysuccinimide and another moiety.
  • R 3 is a monovalent polyethylene glycol with an average molecular weight of about 400 g/mol, 484 g/mol, 1000 g/mol, 1450 g/mol, 1500 g/mol, 2000 g/mol, or 5000 g/mol. In embodiments, R 3 is a monovalent polyethylene glycol with an average molecular weight of about 400 g/mol. In embodiments, R 3 is a monovalent polyethylene glycol with an average molecular weight of about 484 g/mol. In embodiments, R 3 is a monovalent polyethylene glycol with an average molecular weight of about 484 g/mol per arm.
  • R 3 is a monovalent polyethylene glycol with an average molecular weight of about 1000 g/mol. In embodiments, R 3 is a monovalent polyethylene glycol with an average molecular weight of about 1450 g/mol. In embodiments, R 3 is a monovalent polyethylene glycol with an average molecular weight of about 1500 g/mol. In embodiments, R 3 is a monovalent polyethylene glycol with an average molecular weight of about 2000 g/mol. In embodiments, R 3 is a monovalent polyethylene glycol with an average molecular weight of about 5000 g/mol.
  • —X 2 — has the formula:
  • —X 2 -L 3 - has the formula:
  • X 3 is —NH 2 , —COOH, —N-hydroxysuccinimide, or maleimide. In embodiments, X 3 is
  • X 3 is -haloacetyl (eg., iodoacetyl, bromoacetyl, or chloroacetyl). In embodiments, X 3 is pyridyl. In embodiments, X 3 is maleimide. In embodiments, X 3 is —N-hydroxysuccinimide. In embodiments, X 3 is —COOH. In embodiments, X 3 is —NH 2 .
  • z1 is independently 10. In embodiments, z1 is independently 9. In embodiments, z1 is independently 8. In embodiments, z1 is independently 7. In embodiments, z1 is independently 6. In embodiments, z1 is independently 5. In embodiments, z1 is independently 4. In embodiments, z1 is independently 3. In embodiments, z1 is independently 2. In embodiments, z1 is independently 1. In embodiments, z2 is independently 10. In embodiments, z2 is independently 9. In embodiments, z2 is independently 8. In embodiments, z2 is independently 7. In embodiments, z2 is independently 6. In embodiments, z2 is independently 5. In embodiments, z2 is independently 4. In embodiments, z2 is independently 3. In embodiments, z2 is independently 2. In embodiments, z2 is independently 1.
  • the platinum is in a (II) oxidation state. In embodiments, the platinum is in a (II) oxidation state when conjugated to the nanoparticle.
  • the nanoparticle-cell construct has the formula:
  • NP is a nanoparticle and P 1 is a protein optionally attached to a cell (e.g., a stem cell).
  • L 2 , X 1 , L 1 , X 2 , and L 3 are as described herein.
  • the protein is attached to cell and is a cell surface protein.
  • the nanoparticle is a silica nanoparticle.
  • the nanoparticle is typically composed of non-toxic material.
  • the nanoparticle may be an inorganic nanoparticle.
  • the inorganic nanoparticle may be a metal nanoparticle.
  • the inorganic nanoparticle may be a metal oxide nanoparticle.
  • the metal oxide nanoparticle may be titanium oxide or zirconium oxide.
  • the nanoparticle may be titanium.
  • the nanoparticle may be gold.
  • the nanoparticle may be iron.
  • the nanoparticle may be iron oxide.
  • the nanoparticle is a silica nanoparticle including a platinum anti-cancer agent, wherein the platinum anti-cancer agent is conjugated (e.g., covalently bound, bond between the Pt and an oxygen bound to Si) to the silica nanoparticle.
  • the nanoparticle is a silica nanoparticle comprising cisplatin, wherein the cisplatin is conjugated directly to the silica nanoparticle (e.g., a Pt ligand of cisplatin has been replaced with a bond directly to an oxygen of silica).
  • the cisplatin is encapsulated within the silica nanoparticle.
  • the cisplatin is encapsulated within the silica nanoparticle and at the surface.
  • the protein is a cell surface protein.
  • a cell surface protein refers to a protein at the surface of a protein.
  • the cell surface protein is a transmembrane protein.
  • the protein is in contact with the extracellular matrix (e.g., extracellular matrix associated with a cancer cell or in contact with a cancer cell).
  • the protein is in contact with a tumor.
  • the tumor includes stromal cells, immune cells, proteins, and extracellular matrix generated by those cells.
  • immune cells, stromal cells, proteins associate with the immune cells, proteins associated with the stromal cells, and the extracellular matrix generated from immune cells and stromal cells forms part of a tumor.
  • the nanoparticle is incorporated within the cell. In embodiments, the nanoparticle is incorporated within the cell via the enhanced permeability and retention (EPR) effect.
  • EPR enhanced permeability and retention
  • the nanoparticle is further covalently attached to one or more nanoparticle substituents.
  • the nanoparticle substituent includes a polymeric moiety.
  • the polymeric moiety is a polyethylene glycol moiety.
  • the nanoparticle substituents occupy about 5%, 10%, 15%, 20%, 25%, 40%, 50%, 60%, 75%, 80%, 90%, 95%, 99%, or about 100% of the nanoparticle surface.
  • the nanoparticle includes a plurality of nanoparticle substituents of the formula (i) and a plurality of nanoparticle substituents of the formula (ii), and not formula (iii). In embodiments, the nanoparticle includes a plurality of nanoparticle substituents of the formula (i) and a plurality of nanoparticle substituents of the formula (iii), and not formula (ii). In embodiments, the nanoparticle includes a plurality of nanoparticle substituents of the formula (ii) and a plurality of nanoparticle substituents of the formula (iii), and not formula (i).
  • the nanoparticle includes a plurality of nanoparticle substituents of the formula (i), and not formula (ii) or formula (iii). In embodiments, the nanoparticle includes a plurality of nanoparticle substituents of the formula (ii), and not formula (i) or formula (iii). In embodiments, the nanoparticle includes a plurality of nanoparticle substituents of the formula (iii), and not formula (i) or formula (ii).
  • the nanoparticle includes a plurality of nanoparticle substituents of the formula (i) and a plurality of nanoparticle substituents of the formula (ii) in a ratio of about 50:50 to about 80:20.
  • the ratio of a plurality of nanoparticle substituents of the formula (i) and a plurality of substituents of the formula (ii) is about 50:50, 51:49, 52:48, 53:47, 54:46, 55:45, 56:44, 57:43, 58:42, 59:41, 60:40, 61:39, 62:38, 63:37, 64:36, 65:35, 66:34, 67:33, 68:32, 69:31, 70:30, 71:29, 72:28, 73:27, 74:26, 75:25, 76:24, 77:23, 78:22, 79:21, or 80:20.
  • the nanoparticle includes a plurality of nanoparticle substituents of the formula (i) and a plurality of nanoparticle substituents of the formula (iii) in a ratio of about 50:50 to about 80:20.
  • the ratio of a plurality of nanoparticle substituents of the formula (i) and a plurality of substituents of the formula (iii) is about 50:50, 51:49, 52:48, 53:47, 54:46, 55:45, 56:44, 57:43, 58:42, 59:41, 60:40, 61:39, 62:38, 63:37, 64:36, 65:35, 66:34, 67:33, 68:32, 69:31, 70:30, 71:29, 72:28, 73:27, 74:26, 75:25, 76:24, 77:23, 78:22, 79:21, or 80:20.
  • the nanoparticle includes a plurality of nanoparticle substituents of the formula (ii) and a plurality of nanoparticle substituents of the formula (iii) in a ratio of about 50:50 to about 80:20.
  • the ratio of a plurality of nanoparticle substituents of the formula (ii) and a plurality of nanoparticle substituents of the formula (iii) is about 50:50, 51:49, 52:48, 53:47, 54:46, 55:45, 56:44, 57:43, 58:42, 59:41, 60:40, 61:39, 62:38, 63:37, 64:36, 65:35, 66:34, 67:33, 68:32, 69:31, 70:30, 71:29, 72:28, 73:27, 74:26, 75:25, 76:24, 77:23, 78:22, 79:21, or 80:20.
  • the linker is formed by a conjugation or bioconjugation reaction combining a first reactant moiety covalently bonded to the polymeric linker and a second reactant moiety covalently bonded to a protein.
  • the compound formed by such conjugation or bioconjugation reaction (including compounds as described herein) to a cell may be referred to as a nanoparticle-cell construct.
  • composition including a pharmaceutically acceptable excipient and a nanoparticle, cell, or nanoparticle-cell construct, as described herein.
  • compositions (e.g., nanoparticle, cell, or nanoparticle-cell construct) of the present invention can be prepared and administered in a wide variety of oral, parenteral and topical dosage forms.
  • Oral preparations include tablets, pills, powder, dragees, capsules, liquids, lozenges, cachets, gels, syrups, slurries, suspensions, etc., suitable for ingestion by the patient.
  • the compositions (e.g., nanoparticle, cell, or nanoparticle-cell construct) of the present invention can also be administered by injection, that is, intravenously, intramuscularly, intracutaneously, subcutaneously, intraduodenally, or intraperitoneally.
  • compositions (e.g., nanoparticle, cell, or nanoparticle-cell construct) described herein can be administered by inhalation, for example, intranasally.
  • compositions (e.g., nanoparticle, cell, or nanoparticle-cell construct) of the present invention can be administered transdermally. It is also envisioned that multiple routes of administration (e.g., intramuscular, oral, transdermal) can be used to administer the compositions (e.g., nanoparticle, cell, or nanoparticle-cell construct) of the invention.
  • the present invention also provides pharmaceutical compositions comprising a pharmaceutically acceptable excipient and one or more compositions (e.g., nanoparticle, cell, or nanoparticle-cell construct) of the invention.
  • compositions provided by the present invention include compositions wherein the active ingredient is contained in a therapeutically effective amount, i.e., in an amount effective to achieve its intended purpose.
  • a therapeutically effective amount i.e., in an amount effective to achieve its intended purpose.
  • the actual amount effective for a particular application will depend, inter alia, on the condition being treated.
  • such compositions When administered in methods to treat a disease, such compositions will contain an amount of active ingredient effective to achieve the desired result, e.g., modulating the activity of a target molecule, and/or reducing, eliminating, or slowing the progression of cancer symptoms.
  • Determination of a therapeutically effective amount of a composition (e.g., nanoparticle, cell, or nanoparticle-cell construct) of the invention is well within the capabilities of those skilled in the art, especially in light of the detailed disclosure herein.
  • the dosage and frequency (single or multiple doses) administered to a mammal can vary depending upon a variety of factors, for example, whether the mammal suffers from another disease, and its route of administration; size, age, sex, health, body weight, body mass index, and diet of the recipient; nature and extent of symptoms of the disease being treated (e.g., cancer, ovarian cancer, bladder cancer, head and neck cancer, brain cancer, breast cancer, lung cancer, cervical cancer, liver cancer, colorectal cancer, pancreatic cancer, glioblastoma, neuroblastoma, rhabdomyosarcoma, osteosarcoma, renal cancer, renal cell carcinoma, non-small cell lung cancer, uterine cancer, testicular cancer, anal cancer, bile duct cancer, biliary tract cancer, gastrointestinal carcinoid tumors, esophageal cancer, gall bladder cancer, appendix cancer, small intestine cancer, stomach (gastric) cancer, urinary bladder cancer, genitourinary tract
  • compositions e.g., nanoparticle, cell, or nanoparticle-cell construct
  • Adjustment and manipulation of established dosages are well within the ability of those skilled in the art.
  • compositions e.g., nanoparticle, cell, or nanoparticle-cell construct
  • LD 50 the amount of compositions (e.g., nanoparticle, cell, or nanoparticle-cell construct) lethal in 50% of the population)
  • ED 50 the amount of compositions (e.g., nanoparticle, cell, or nanoparticle-cell construct) effective in 50% of the population).
  • Compositions e.g., nanoparticle, cell, or nanoparticle-cell construct
  • Therapeutic index data obtained from cell culture assays and/or animal studies can be used in formulating a range of dosages for use in humans.
  • the dosage of such compositions preferably lies within a range of plasma concentrations that include the ED 50 with little or no toxicity.
  • the dosage may vary within this range depending upon the dosage form employed and the route of administration utilized. See, e.g. Fingl et al., In: T HE P HARMACOLOGICAL B ASIS OF T HERAPEUTICS , Ch. 1, p. 1, 1975.
  • the exact formulation, route of administration and dosage can be chosen by the individual physician in view of the patient's condition and the particular method in which the composition (e.g., nanoparticle, cell, or nanoparticle-cell construct) is used.
  • the neutral forms of the compositions may be regenerated by contacting the salt with a base or acid and isolating the parent compound in the conventional manner.
  • the parent form of the composition e.g., nanoparticle, cell, or nanoparticle-cell construct
  • compositions described herein of the present invention can exist in unsolvated forms as well as solvated forms, including hydrated forms.
  • the solvated forms are equivalent to unsolvated forms and are intended to be encompassed within the scope of the present invention.
  • Certain compounds of the present invention may exist in multiple crystalline or amorphous forms. In general, all physical forms are equivalent for the uses contemplated by the present invention and are intended to be within the scope of the present invention.
  • compositions of the present invention are useful for parenteral administration, such as intravenous (IV) administration or administration into a body cavity or lumen of an organ.
  • parenteral administration such as intravenous (IV) administration or administration into a body cavity or lumen of an organ.
  • the formulations for administration will commonly include a solution of the compositions of the present invention dissolved in a pharmaceutically acceptable carrier.
  • acceptable vehicles and solvents that can be employed are water and Ringer's solution, an isotonic sodium chloride.
  • sterile fixed oils can conventionally be employed as a solvent or suspending medium.
  • any bland fixed oil can be employed including synthetic mono- or diglycerides.
  • fatty acids such as oleic acid can likewise be used in the preparation of injectables. These solutions are sterile and generally free of undesirable matter.
  • formulations may be sterilized by conventional, well known sterilization techniques.
  • the formulations may contain pharmaceutically acceptable auxiliary substances as required to approximate physiological conditions such as pH adjusting and buffering agents, toxicity adjusting agents, e.g., sodium acetate, sodium chloride, potassium chloride, calcium chloride, sodium lactate and the like.
  • concentration of the compositions of the present invention in these formulations can vary widely, and will be selected primarily based on fluid volumes, viscosities, body weight, and the like, in accordance with the particular mode of administration selected and the patient's needs.
  • the formulation can be a sterile injectable preparation, such as a sterile injectable aqueous or oleaginous suspension.
  • This suspension can be formulated according to the known art using those suitable dispersing or wetting agents and suspending agents.
  • the sterile injectable preparation can also be a sterile injectable solution or suspension in a nontoxic parenterally-acceptable diluent or solvent, such as a solution of 1,3-butanediol.
  • the pharmaceutical preparation is preferably in unit dosage form.
  • the preparation is subdivided into unit doses containing appropriate quantities of the active component.
  • the unit dosage form can be a packaged preparation, the package containing discrete quantities of preparation, such as packeted tablets, capsules, and powders in vials or ampoules.
  • the unit dosage form can be a capsule, tablet, cachet, or lozenge itself, or it can be the appropriate number of any of these in packaged form.
  • compositions e.g., nanoparticle, cell, or nanoparticle-cell construct
  • cancer e.g. ovarian cancer, bladder cancer, head and neck cancer, brain cancer, breast cancer, lung cancer, cervical cancer, liver cancer, colorectal cancer, pancreatic cancer, glioblastoma, neuroblastoma, rhabdomyosarcoma, osteosarcoma, renal cancer, renal cell carcinoma, non-small cell lung cancer, uterine cancer, testicular cancer, anal cancer, bile duct cancer, biliary tract cancer, gastrointestinal carcinoid tumors, esophageal cancer, gall bladder cancer, appendix cancer, small intestine cancer, stomach (gastric) cancer, urinary bladder cancer, genitourinary tract cancer, endometrial cancer, nasopharyngeal cancer, head and neck squamous cell carcinoma, or prostate cancer), or with adjunctive agents that may
  • cancer e.g. ovarian cancer, bladder cancer, head and neck cancer,
  • the nanoparticles, cells, or nanoparticle-cell constructs described herein can be co-administered with conventional chemotherapeutic agents including alkylating agents (e.g., cyclophosphamide, ifosfamide, chlorambucil, busulfan, melphalan, mechlorethamine, uramustine, thiotepa, nitrosoureas, etc.), anti-metabolites (e.g., 5-fluorouracil, azathioprine, methotrexate, leucovorin, capecitabine, cytarabine, floxuridine, fludarabine, gemcitabine, pemetrexed, raltitrexed, etc.), plant alkaloids (e.g., vincristine, vinblastine, vinorelbine, vindesine, podophyllotoxin, paclitaxel, docetaxel, etc.), topoisomerase inhibitors (e.g.,
  • nanoparticles, cells, or nanoparticle-cell constructs or drugs described herein can also be co-administered with conventional hormonal therapeutic agents including, but not limited to, steroids (e.g., dexamethasone), finasteride, aromatase inhibitors, tamoxifen, and gonadotropin-releasing hormone agonists (GnRH) such as goserelin.
  • steroids e.g., dexamethasone
  • finasteride e.g., aromatase inhibitors
  • tamoxifen e.g., tamoxifen
  • gonadotropin-releasing hormone agonists GnRH
  • the nanoparticles, cells, or nanoparticle-cell constructs or drugs described herein can be co-administered with conventional radiotherapeutic agents including, but not limited to, radionuclides such as 47 Sc, 64 Cu, 67 Cu, 89 Sr, 86 Y, 87 Y, 90 Y, 105 Rh, 111 Ag, 111 In, 117m Sn, 149 Pm, 153 Sm, 166 Ho, 177 Lu, 186 Re, 188 Re, 211 At, and 212 Bi, optionally conjugated to antibodies directed against tumor antigens.
  • radionuclides such as 47 Sc, 64 Cu, 67 Cu, 89 Sr, 86 Y, 87 Y, 90 Y, 105 Rh, 111 Ag, 111 In, 117m Sn, 149 Pm, 153 Sm, 166 Ho, 177 Lu, 186 Re, 188 Re, 211 At, and 212 Bi, optionally conjugated to antibodies directed against tumor antigens.
  • compositions of the present invention may be sterilized by conventional, well-known sterilization techniques or may be produced under sterile conditions.
  • Aqueous solutions can be packaged for use or filtered under aseptic conditions and lyophilized, the lyophilized preparation being combined with a sterile aqueous solution prior to administration.
  • the compositions can contain pharmaceutically acceptable auxiliary substances as required to approximate physiological conditions, such as pH adjusting and buffering agents, tonicity adjusting agents, wetting agents, and the like, e.g., sodium acetate, sodium lactate, sodium chloride, potassium chloride, calcium chloride, sorbitan monolaurate, and triethanolamine oleate.
  • Formulations suitable for oral administration can comprise: (a) liquid solutions, such as an effective amount of a packaged nanoparticles, cells, or nanoparticle-cell constructs or drug suspended in diluents, e.g., water, saline, or PEG 400; (b) capsules, sachets, or tablets, each containing a predetermined amount of a nanoparticles, cells, or nanoparticle-cell constructs or drug, as liquids, solids, granules or gelatin; (c) suspensions in an appropriate liquid; and (d) suitable emulsions.
  • liquid solutions such as an effective amount of a packaged nanoparticles, cells, or nanoparticle-cell constructs or drug suspended in diluents, e.g., water, saline, or PEG 400
  • capsules, sachets, or tablets each containing a predetermined amount of a nanoparticles, cells, or nanoparticle-cell constructs or drug, as liquids, solids,
  • Tablet forms can include one or more of lactose, sucrose, mannitol, sorbitol, calcium phosphates, corn starch, potato starch, microcrystalline cellulose, gelatin, colloidal silicon dioxide, talc, magnesium stearate, stearic acid, and other excipients, colorants, fillers, binders, diluents, buffering agents, moistening agents, preservatives, flavoring agents, dyes, disintegrating agents, and pharmaceutically compatible carriers.
  • Lozenge forms can comprise a nanoparticles, cells, or nanoparticle-cell constructs or drug in a flavor, e.g., sucrose, as well as pastilles comprising the polypeptide or peptide fragment in an inert base, such as gelatin and glycerin or sucrose and acacia emulsions, gels, and the like, containing, in addition to the polypeptide or peptide, carriers known in the art.
  • a flavor e.g., sucrose
  • an inert base such as gelatin and glycerin or sucrose and acacia emulsions, gels, and the like, containing, in addition to the polypeptide or peptide, carriers known in the art.
  • the nanoparticles, cells, or nanoparticle-cell constructs or drug (e.g., anti-cancer agent) of choice, alone or in combination with other suitable components, can be made into aerosol formulations (i.e., they can be “nebulized”) to be administered via inhalation. Aerosol formulations can be placed into pressurized acceptable propellants, such as dichlorodifluoromethane, propane, nitrogen, and the like.
  • Suitable formulations for rectal administration include, for example, suppositories, which comprises an effective amount of a packaged nanoparticles, cells, or nanoparticle-cell constructs or drug with a suppository base.
  • Suitable suppository bases include natural or synthetic triglycerides or paraffin hydrocarbons.
  • gelatin rectal capsules which contain a combination of the nanoparticles, cells, or nanoparticle-cell constructs or drug of choice with a base, including, for example, liquid triglycerides, polyethylene glycols, and paraffin hydrocarbons.
  • Formulations suitable for parenteral administration include aqueous and non-aqueous, isotonic sterile injection solutions, which can contain antioxidants, buffers, bacteriostats, and solutes that render the formulation isotonic with the blood of the intended recipient, and aqueous and non-aqueous sterile suspensions that can include suspending agents, solubilizers, thickening agents, stabilizers, and preservatives. Injection solutions and suspensions can also be prepared from sterile powders, granules, and tablets.
  • compositions can be administered, for example, by intravenous infusion, orally, topically, intraperitoneally, intravesically, or intrathecally.
  • Parenteral administration, oral administration, and intravenous administration are the preferred methods of administration.
  • the formulations of compositions e.g., nanoparticle, cell, or nanoparticle-cell construct
  • the pharmaceutical preparation is preferably in unit dosage form.
  • the preparation is subdivided into unit doses containing appropriate quantities of the active component, e.g., nanoparticles, cells, or nanoparticle-cell constructs or drug.
  • the unit dosage form can be a packaged preparation, the package containing discrete quantities of preparation, such as packeted tablets, capsules, and powders in vials or ampoules.
  • the unit dosage form can be a capsule, tablet, cachet, or lozenge itself, or it can be the appropriate number of any of these in packaged form.
  • the composition can, if desired, also contain other compatible therapeutic agents.
  • a method of treating cancer in a patient in need of such treatment including administering to a subject in need thereof a therapeutically effective amount of the nanoparticle, the cell, or the nanoparticle-cell construct, as described herein.
  • the method is administering to a subject in need thereof a therapeutically effective amount of the nanoparticle as described herein.
  • the method is administering to a subject in need thereof a therapeutically effective amount of the cell as described herein.
  • the method is administering to a subject in need thereof a therapeutically effective amount of the nanoparticle-cell construct as described herein.
  • the cancer is ovarian cancer, bladder cancer, head and neck cancer, brain cancer, breast cancer, lung cancer, cervical cancer, liver cancer, colorectal cancer, pancreatic cancer, glioblastoma, neuroblastoma, rhabdomyosarcoma, osteosarcoma, renal cancer, renal cell carcinoma, non-small cell lung cancer, uterine cancer, testicular cancer, anal cancer, bile duct cancer, biliary tract cancer, gastrointestinal carcinoid tumors, esophageal cancer, gall bladder cancer, appendix cancer, small intestine cancer, stomach (gastric) cancer, urinary bladder cancer, genitourinary tract cancer, endometrial cancer, nasopharyngeal cancer, head and neck squamous cell carcinoma, or prostate cancer.
  • the cancer is ovarian cancer, bladder cancer, head and neck cancer, prostate cancer, brain cancer, breast cancer, lung cancer, cervical cancer, liver cancer, bone cancer, or spinal cancer.
  • the cancer is ovarian cancer, bladder
  • the nanoparticle, cell, or nanoparticle-cell construct is administered via intraperitoneal injection, intratumoral injection, intraurethral injection, or intramuscular injection. In embodiments, the nanoparticle, cell, or nanoparticle-cell construct is administered via intraperitoneal injection. In embodiments, the nanoparticle, cell, or nanoparticle-cell construct is administered via intraurethral injection. In embodiments, the nanoparticle, cell, or nanoparticle-cell construct is administered via intramuscular injection. In embodiments, the nanoparticle, cell, or nanoparticle-cell construct is administered via intratumoral injection.
  • a silica nanoparticle comprising an unmodified platinum anti-cancer agent.
  • silica nanoparticle of embodiment P1 wherein the unmodified platinum anti-cancer agent is conjugated directly to the silica nanoparticle.
  • silica nanoparticle of embodiments P1 or P2, wherein the unmodified platinum anti-cancer agent is cisplatin, carboplatin, oxaliplatin, nedaplatin, lobaplatin, or heptaplatin.
  • the detectable agent is a radioisotope, fluorophore, electron-dense reagent, enzyme, biotin, paramagnetic agent, or magnetic agent.
  • a cell comprising the nanoparticle of one of embodiments P1 to P9.
  • a pharmaceutical composition comprising a pharmaceutically acceptable excipient and the silica nanoparticle of any one of embodiments P1 to P9 or the cell of one of embodiments P10 or P11.
  • a nanoparticle-cell construct comprising a nanoparticle covalently attached to a protein through a covalent linker, said covalent linker having the formula: -L 2 -X 1 -L 1 -X 2 -L 3 -; (Ia) or -L 2 -X 2 -L 3 -; (Ib)
  • nanoparticle-cell construct of embodiment P13 wherein the nanoparticle is a silica nanoparticle.
  • nanoparticle-cell construct of any of embodiments P13 to P15, wherein the nanoparticle comprises a platinum anti-cancer agent conjugated directly to the nanoparticle.
  • nanoparticle-cell construct of any one of embodiments P13 to P16, wherein the nanoparticle comprises cisplatin.
  • L 1 is polyethylene glycol with an average molecular weight of 400, 484, 1000, 1450, 1500, 2000, or 5000.
  • nanoparticle-cell construct of embodiment P25 wherein said nanoparticle substituent is: -L 2 -X 1 —R 3 ; (i) -L 2 -X 1 -L 1 -X 3 ; (ii) or -L 2 -X 3 ; (iii)
  • nanoparticle-cell construct of any one of embodiments P26 to P28 comprising a plurality of nanoparticle substituents of the formula (i) and a plurality of nanoparticle substituents of the formula (ii) in a ratio of about 50:50 to about 80:20.
  • nanoparticle-cell construct of any one of embodiments P26 to P28 comprising a plurality of nanoparticle substituents of the formula (ii) and a plurality of nanoparticle substituents of the formula (iii) in a ratio of about 50:50 to about 80:20.
  • nanoparticle-cell construct of any one of embodiments P26 to P28 comprising a plurality of nanoparticle substituents of the formula (i) and a plurality of nanoparticle substituents of the formula (iii) in a ratio of about 50:50 to about 80:20.
  • each L 1 is independently a linear or branched polymeric linker.
  • a pharmaceutical composition comprising a pharmaceutically acceptable excipient and a construct of any one of embodiments P13 to P32.
  • a method of treating cancer in a subject in need of such treatment comprising administering to the subject a therapeutically effective amount of the nanoparticle, or pharmaceutical composition thereof, of any one of embodiments P1 to P9, the cell, or pharmaceutical composition thereof of embodiments P10 or P11, or the nanoparticle-cell construct of any one of embodiments P13 to P32, or a pharmaceutical composition thereof of embodiment 33.
  • the cancer is ovarian cancer, bladder cancer, head and neck cancer, brain cancer, breast cancer, lung cancer, cervical cancer, bone cancer, spinal cancer, liver cancer, colorectal cancer, pancreatic cancer, glioblastoma, neuroblastoma, rhabdomyosarcoma, osteosarcoma, renal cancer, renal cell carcinoma, non-small cell lung cancer, uterine cancer, testicular cancer, anal cancer, bile duct cancer, biliary tract cancer, gastrointestinal carcinoid tumors, esophageal cancer, gall bladder cancer, appendix cancer, small intestine cancer, stomach (gastric) cancer, urinary bladder cancer, genitourinary tract cancer, endometrial cancer, nasopharyngeal cancer, head and neck squamous cell carcinoma, or prostate cancer.
  • cancer is ovarian cancer, bladder cancer, head and neck cancer, prostate cancer, brain cancer, breast cancer, lung cancer, cervical cancer, liver cancer, bone cancer, or spinal cancer.
  • nanoparticle, cell, or nanoparticle-cell construct is administered via intraperitoneal injection, intratumoral injection, intraurethral injection, or intramuscular injection.
  • a silica nanoparticle comprising a platinum anti-cancer agent, wherein the platinum anti-cancer agent is conjugated to silica directly, though an oxygen linker, or through a nitrogen linker.
  • silica nanoparticle of embodiment 1, wherein the platinum anti-cancer agent is conjugated to silica though an oxygen linker.
  • the detectable agent is a radioisotope, fluorophore, electron-dense reagent, enzyme, biotin, paramagnetic agent, or magnetic agent.
  • a cell comprising the silica nanoparticle of one of embodiments 1 to 12.
  • a pharmaceutical composition comprising a pharmaceutically acceptable excipient and the silica nanoparticle of any one of embodiments 1 to 12 or the cell of one of embodiments 13 or 14.
  • a nanoparticle-cell construct comprising an inorganic nanoparticle covalently attached to a protein through a covalent linker, said covalent linker having the formula: -L 2 -X 1 -L 1 -X 2 -L 3 -; (Ia) or -L 2 -X 2 -L 3 -; (Ib)
  • nanoparticle-cell construct of any one of embodiments 18 to 19, wherein the nanoparticle comprises cisplatin.
  • L 1 is polyethylene glycol with an average molecular weight of 400 g/mol, 484 g/mol, 1000 g/mol, 1450 g/mol, 1500 g/mol, 2000 g/mol, or 5000 g/mol.
  • nanoparticle-cell construct of embodiment 28, wherein said nanoparticle substituent is: -L 2 -X 1 —R 3 ; (i) -L 2 -X 1 -L 1 -X 3 ; (ii) or -L 2 -X 3 ; (iii)
  • nanoparticle-cell construct of any one of embodiments 29 to 31 comprising a plurality of nanoparticle substituents of the formula (i) and a plurality of nanoparticle substituents of the formula (ii) in a ratio of from about 50:50 to about 80:20.
  • nanoparticle-cell construct of any one of embodiments 29 to 31 comprising a plurality of nanoparticle substituents of the formula (ii) and a plurality of nanoparticle substituents of the formula (iii) in a ratio of from about 50:50 to about 80:20.
  • nanoparticle-cell construct of any one of embodiments 29 to 31 comprising a plurality of nanoparticle substituents of the formula (i) and a plurality of nanoparticle substituents of the formula (iii) in a ratio of from about 50:50 to about 80:20.
  • each L 1 is independently a linear or branched polymeric linker.
  • a pharmaceutical composition comprising a pharmaceutically acceptable excipient and a nanoparticle-cell construct of any one of embodiments 16 to 35.
  • a method of treating cancer in a subject in need of such treatment comprising administering to the subject a therapeutically effective amount of the nanoparticle of one of embodiments 1 to 12, the cell of one of embodiments 13 to 14, the pharmaceutical composition of embodiment 15 or 36, or the nanoparticle-cell construct of one of embodiments 16 to 35.
  • the cancer is ovarian cancer, bladder cancer, head and neck cancer, brain cancer, breast cancer, lung cancer, cervical cancer, bone cancer, spinal cancer, liver cancer, colorectal cancer, pancreatic cancer, glioblastoma, neuroblastoma, rhabdomyosarcoma, osteosarcoma, renal cancer, renal cell carcinoma, non-small cell lung cancer, uterine cancer, testicular cancer, anal cancer, bile duct cancer, biliary tract cancer, gastrointestinal carcinoid tumors, esophageal cancer, gall bladder cancer, appendix cancer, small intestine cancer, stomach (gastric) cancer, urinary bladder cancer, genitourinary tract cancer, endometrial cancer, nasopharyngeal cancer, head and neck squamous cell carcinoma, or prostate cancer.
  • cancer is ovarian cancer, bladder cancer, head and neck cancer, prostate cancer, brain cancer, breast cancer, lung cancer, cervical cancer, liver cancer, bone cancer, or spinal cancer.
  • nanoparticle, cell, or nanoparticle-cell construct is administered via intraperitoneal injection, intratumoral injection, intraurethral injection, or intramuscular injection.
  • nanoparticle, cell, or nanoparticle-cell construct is administered via intraperitoneal injection.
  • Applicants have optimized the preparation to encapsulate an unmodified cisplatin precursor by silica nanoparticles (NPs) via a one-pot reaction, and these cisplatin-NPs demonstrated delayed drug release over 3 days via in vitro efficacy MTT assay.
  • NPs silica nanoparticles
  • Our data demonstrated that NSC-NP constructs have superior accumulation and retention of Pt in tumors than both free cisplatin and free cisplatin-NPs.
  • Current work focuses on the long term survival of ovarian cancer-bearing mice treated with NSC-NP constructs.
  • TEOS tetraethyl orthosilicate
  • SiNP-Cis was collected by centrifugation (3220 g, 10 min). The supernatant was discarded, the NP pellet was redispersed in 2 mL EtOH and transferred to a 2 mL eppendorf. SiNP-Cis was washed via repeated centrifugation by 2 more times with EtOH and 3 more times with MilliQ water (21,000 g, 1.5 min). The NP solution was sonicated in between washes to assist their redispersion back into solution. After the final wash, SiNP-Cis was dispersed in 0.5 mL MilliQ water and stored at 4° C.
  • TEOS tetraethyl orthosilicate
  • Fluorescently-labeled SiNPs were collected by centrifugation (3220 g, 10 min). The supernatant was discarded, the NP pellet was redispersed in 2 mL EtOH and transferred to a 2 mL eppendorf SiNPs were washed via repeated centrifugation by 2 more times with EtOH and 3 more times with MilliQ water (21,000 g, 1.5 min). The NP solution was sonicated in between washes to assist their redispersion back into solution. After the final wash, SiNPs were dispersed in MilliQ water and stored at 4° C.
  • PEGylated SiNPs were collected and washed by repeated centrifugation at 21,000 g for 1 min (3 times with MilliQ water). PEGylated SiNPs were resuspended in MilliQ water and stored at 4° C.
  • silica nanoparticles terminated with —NH 2 with branched PEGs selected from Table 1.
  • SiNP—NH 2 in MilliQ was washed 3 times with PBS to convert their solvent to PBS followed by the addition of a TFP-(PEG 11 ) 3 or N-Hydroxysuccinimide-(PEG 24 ) 3 solution in PBS.
  • N-Hydroxysuccinimide is alternatively written as NHS. The mixture was placed in a shaker and incubated at 37° C. overnight.
  • each amine group NH 2 — on the NP surface takes up 0.6 nm 2 and each amine functional group reacts with one activated ester group (TFP- or N-Hydroxysuccinimide-) on the branched PEG molecules.
  • TBP- or N-Hydroxysuccinimide- activated ester group
  • 10-fold molar excess of PEG to the number of amine groups on the SiNP surface was used in the reaction.
  • PEGylated SiNPs were collected and washed by repeated centrifugation at 21,000 g for 1 min (3 times with MilliQ water). PEGylated SiNPs were resuspended in MilliQ water and stored at 4° C.
  • a preferred polymeric linker is
  • NHS is N-hydroxysuccinimide
  • Variables tested during the synthesis of SiNP-Cis 1. The amount of cisplatin to load to each standard batch of SiNPs. The amount of silica precursor and the solvent system during the synthesis was kept consistent. The amount of cisplatin added during the reaction was varied to check the loading efficiency. 2. The type of drug: cisplatin vs. carboplatin. 3. The scale of the reaction. When the reaction was scaled up, it was tested whether the formation of SiNPs and the loading of cisplatin was consistent. 4. The stirring speed of the reaction. 5. The stability of cisplatin in the NPs. 6. Surface functionalization of SiNP-Cis. One batch of SiNP-Cis was PEGylated.
  • Variable 1 The amount of cisplatin. Comparing to the control nanoparticles SiNP-empty that do not have any drug added, SiNP-Cis particles loaded with 3 mg, 6 mg, and 12 mg cisplatin also maintained their morphology. They appear to be roughly the same size and shape as the control NPs. They are all monodisperse, and colloidally stable in water. The amount of Pt in cisplatin was quantified by ICP-MS: 10 ⁇ L of SiNP-Cis was added to a 15 mL tube followed by the addition of 1 mL of 70% concentrated nitric acid HNO3. SiNP-Cis was digested in 70% HNO3 for 1 h, at room temperature.
  • Variable 2 The type of drug encapsulated by SiNP.
  • the synthesis of SiNP-Carbo was the same as a standard synthetic preparation of SiNP-Cis. Instead of 12 mg cisplatin, 12 mg of carboplatin was added to the reaction mixture. Comparing to SiNP-Cis particles, SiNP-Carbo also maintained their morphology. They appear to be roughly the same size and shape to SiNP-Cis.
  • Variable 3 The scale of the reaction. The syntheses of SiNP-Cis-3 ⁇ and SiNP-Cis-5 ⁇ followed the same procedure as in the 1 ⁇ standard reaction with triple (3 ⁇ ) or quintuple (5 ⁇ ) the amount of reagents. Comparing to 1 ⁇ SiNP-Cis particles, scaled up SiNP-Cis also maintained their morphology. They appear to be roughly the same size and shape to SiNP-Cis. The amount of Pt in these NPs was measured by ICP-MS.
  • Variable 4 The stirring speed. 1 ⁇ reaction was stirred at speed 4 (500 rpm) whereas the 5 ⁇ reaction was stirred at speed 4 and generated semi-empty SiNPs. This concludes us to stir all 5 ⁇ reactions at speed 3 (400 rpm).
  • polystyrene serological pipettes are not chemical resistant and they should not be used to add cyclohexane or triton X-100 or hexanol to the reaction mixture.
  • SiNP-Cis appeared to have some “empty” spots on them by TEM. This is due to dissolved polystryene from the pipettes that got incorporated to the SiNPs. This problem was solved by using all syringes to add the solvents.
  • Variable 5 The stability of SiNP-Cis in PBS and DMEM.
  • SiNP-Cis were suspended in either full Dulbecco's Modified Eagle's Medium (DMEM) media or Phosphate-buffered saline (PBS) with 2% human serum albumin. They were incubated at 37° C. for 10 min, 30 min, 1 h, and 24 h. At each time point, the NPs were pelleted to the bottom of the eppendorf tube and a small fraction of the supernatant was collected (10 uL) for ICP-MS quantification of Pt. NPs were redispersed back into the solution by gently shaking. The 10 uL supernatant sample was added to a 15 mL tube and 1 mL concentrated 70% HNO 3 acid was added to digest the samples at room temperature for 1 h before measurements.
  • DMEM Dulbecco's Modified Eagle's Medium
  • PBS Phosphate-buffered saline
  • SiNP-Cis were stable in full DMEM media and PBS with 2% human serum albumin. After 24 h incubation at 37° C., only about 3% of Pt was lost in the supernatant.
  • Variable 6 Surface modification of SiNP-Cis-PEG. PEGylated SiNP-Cis retained their morphology as they had very similar shape and size to SiNP-Cis. The amount of Pt in SiNP-Cis-PEG was measured by ICP-MS, to be 0.1 ⁇ g/uL Pt.
  • NSCs were labeled with PEGylated SiNPs at both 4° C. and 37° C. for 30 min in FIG. 21 A , and only at 37° C. for 30 min in FIG. 21 B .
  • the amount of Mal-PEG on the NP surface was low and NSCs were not optimally labeled with SiNPs.
  • NSCs were labeled with much more NP-PEG11-3400. It appears that the shorter functional Mal-PEG3400 works better than the Mal-PEG5000.
  • Mal-PEG2000 and Mal-PEG3400 appear to work better than Mal-PEG5000. At 80%:20%, Mal-PEG2000 works much better than Mal-PEG3400 and Mal-PEG5000 as it was able to label NSCs while the other two could not.
  • TEM experiments indicate empty silica nanoparticles (e.g., not loaded with a platinum containing compound) and platinum-loaded silica nanoparticles (e.g., Cisplatin loaded silica nanoparticles) have similar spherical morphology and size with a mean diameter of approximately 51 nm.
  • XPS survey spectrum of platinum-loaded silica nanoparticles shows elemental composition of the NPs.
  • High resolution spectra of platinum-loaded silica nanoparticles shows that Pt on the Si NPs is on +II state. Due to the absence of the chlorine band in the 198-200 eV region, it appears chlorine is not bound to the platinum following cisplatin conjugation to the silica nanoparticle.
  • modulating the synthetic conditions i.e. changing the ratio of TEOS to NH 4 OH as seen in Table 5, changed the release profile and stability of the Cis-SiNPs and empty SiNPs.
  • Condition AA Decreasing the NH 4 OH relative to AB, the silica is etched and the platinum is released in the supernatant at a similar rate to Cis-SiNPs synthesized according to AB. Approximately 60-75% of the platinum is released in the supernatant and 25-45% of the platinum remains in the nanoparticle.
  • Condition BB Increasing the TEOS relative to AB, the nanoparticles become more dense and they are more stable. The silica is not etched and there is no burst release of the platinum. Approximately 10-15% of the platinum is released to the supernatant and 80-90% of the platinum is retained in the nanoparticle.
  • Condition BA Increasing the TEOS and decreasing the NH 4 OH relative to AB.
  • the nanoparticles synthesized by this method are more stable and have a desirable release profile. Approximately 10% of the platinum is released into the supernatant and 90-100% of the platinum is retained in the nanoparticle.
  • Nonionic surfactant Triton X-100 (10 mL), Cyclohexane (35.8 mL), Hexanol (9 mL), TEOS (1000 ⁇ L), H2O (1.7 mL), 60 mg Cis cis-diamminedichloridoplatinum(II) (Cisplatin), 5 h later, ammonium hydroxide (300 uL), Stirring 16 h.
  • the resulting NPs precipitated in Ethanol centrifugation (4000 rpm, 10 min)
  • the nanoparticles synthesized via the AB method are sometimes referred to as ‘Old Cis’ and the nanoparticles synthesized according to the BA method are sometimes referred to as ‘New Cis.’
  • MTT assay measures the cytotoxicity of free drug cisplatin, free NP carrier, and SiNP-Cis on cells.
  • This assay was done in 96-well plates. To prepare the cells, a three step procedure was followed: 1. Plate 4000 cells/well in 100 uL full media to the 96-well plate 2. Each cell line was plated in 1 plates for each time point, for 3 days. NSCs and Skov3 cells were adhered well overnight.
  • MTT assay protocol 1) at each time point (i.e. day1), create a 1 mg/mL MTT solution in warm media. 2) Filter the MTT using a sterile filter and syringe. 3) To each well, remove the old media, then add the new media with 1 mg/mL MTT. 4) Incubate cells at 37° C. for 1 hours, check every half an hour or so (make sure you see a gradient of purple color. Not too strong or too light). 5) Remove the MTT/media using a multi-well pipette. 6) Add in 100 ⁇ L of DMSO (does not need to be filtered) to dissolve the formazan crystals produced by the cells. To make sure all the crystals were dissolved, shake the plates gently and leave the plate at r.t. for 30 min before reading the plate. 7) Place the 96-well plate in the plate reader and measure the absorbance at 570 nm.
  • NSC ⁇ SiNP-Cis labeling studies to predict Pt loading The experimental protocol is as follows: 1. 1M NSCs were plated in each well. 2. Old media of NSCs were removed and 1.5 mL of fresh media was added to each well before loading SiNP-Cis. 3. NSCs were incubated with SiNP-Cis at 37° C. for 1 h. 4. After 1 h, the media containing free NPs were removed and cells were washed once with PBS. 5. NSCs were then trypsinized to lift off the plate and collected by centrifugation (850 g, 3 min). 6. The supernatant was removed and the cell pellet was digested in 1 mL of concentrated HNO3. 7. The amount of Pt in 1M cells was measured by ICP-MS.
  • Group 2 cisplatin powder was dissolved in PBS with 2% HBA and dilutions were made to reach a final concentration of 85 ⁇ g Pt/mL for injection.
  • Group 3 Pt concentration in SiNP-Cis was measured by ICP-MS and dilutions were made to reach a final concentration of 85 ⁇ g Pt/mL for injection.
  • NSC+SiNP-Cis sample i) Each T175 flask containing roughly 10 M NSCs would be used to for 1 animal; ii) Old media of NSCs were removed and 7.5 mL of fresh media was added to each well before loading 1 mL SiNP-Cis; iii) NSCs were incubated with SiNP-Cis at 37° C.
  • Each tumor or organ was added to a 15 mL tube and it was digested by 1 mL of 70% HNO3 at 70° C. overnight (Livers needed 2 mL of conc. Acid). 4 mL of MilliQ water was added to each tube to dilute the samples prior to ICP-MS measurements. Due to the different amount of Pt injected to animals at the beginning, the measured Pt number in Group 2 and Group 3 were adjusted accordingly to match the amount of Pt in Group 4.
  • Ovarian cancer is a deadly disease that afflicts approximately 22,000 women per year in the US. Once the disease reaches stage III and has metastasized to the abdominal cavity, the 5-year survival rate is only 34%.
  • Our goal is to develop stem cell/nanoparticle constructs for targeted and selective tumor killing in patients suffering from late stage ovarian cancer.
  • Neural Stem Cells are appealing for use as targeted delivery platforms in the abdomen, as they have demonstrated inherent tumor tropic properties to ovarian cancer cells in vitro and in vivo following IP administration.
  • NSCs do not intrinsically have any anti-tumor efficacy. As NSC-based therapy moves into the clinic, there is a need to develop complementary techniques to enable targeted delivery of chemotherapeutics by NSCs.
  • NPs nanoparticles
  • SiNPs model fluorescent silica NPs
  • the SiNPs were characterized by TEM, SEM, DLS, zetasizer, and the amount of Pt was quantified by ICP-MS. In vitro efficacy tests of these cisplatin-NPs demonstrated delayed drug release over 3 days.
  • NSC-NP constructs have much superior accumulation of Pt in tumors than both free cisplatin and free cisplatin-NPs.
  • Current work focuses on the long term survival of ovarian cancer-bearing mice treated with NSC-NP constructs.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Ceramic Engineering (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nanotechnology (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
US16/066,628 2015-12-31 2016-12-28 Nanoparticle-cell construct with platinum anti-cancer agent Active 2037-02-24 US11696959B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US16/066,628 US11696959B2 (en) 2015-12-31 2016-12-28 Nanoparticle-cell construct with platinum anti-cancer agent

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562274034P 2015-12-31 2015-12-31
PCT/US2016/068978 WO2017117275A1 (fr) 2015-12-31 2016-12-28 Nanoparticule de silice contenant un agent anticancéreux à base de platine
US16/066,628 US11696959B2 (en) 2015-12-31 2016-12-28 Nanoparticle-cell construct with platinum anti-cancer agent

Publications (2)

Publication Number Publication Date
US20190022246A1 US20190022246A1 (en) 2019-01-24
US11696959B2 true US11696959B2 (en) 2023-07-11

Family

ID=59225639

Family Applications (1)

Application Number Title Priority Date Filing Date
US16/066,628 Active 2037-02-24 US11696959B2 (en) 2015-12-31 2016-12-28 Nanoparticle-cell construct with platinum anti-cancer agent

Country Status (2)

Country Link
US (1) US11696959B2 (fr)
WO (1) WO2017117275A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020092342A1 (fr) * 2018-10-29 2020-05-07 University Of Georgia Research Foundation, Inc. Nanocapsules de médicament à base de silice

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050037075A1 (en) * 2003-06-06 2005-02-17 Farokhzad Omid C. Targeted delivery of controlled release polymer systems
US20060240009A1 (en) * 2001-03-26 2006-10-26 Samuel Zalipsky Liposome composition for improved intracellular delivery of a therapeutic agent
US20090181398A1 (en) * 2005-04-28 2009-07-16 Christina Bauer Nanoparticle conjugates
US20100233085A1 (en) 2009-03-10 2010-09-16 Korea Institute Of Science And Technology Ionic complex nanoparticles for detecting heparanase activities and method for preparing the same
US20120252140A1 (en) * 2009-12-25 2012-10-04 Konica Minolta Medical & Graphic, Inc. Fluorescent substance-containing silica nanoparticles and biosubstance labeling agent
US20130039848A1 (en) * 2009-07-02 2013-02-14 Cornell University Fluorescent silica-based nanoparticles
US20130337066A1 (en) 2011-06-02 2013-12-19 The Regents Of The University Of California Membrane Encapsulated Nanoparticles and Method of Use
US20140079774A1 (en) 2011-04-28 2014-03-20 Stc.Unm Porous nanoparticle-supported lipid bilayers (protocells) for targeted delivery and methods of using same

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060240009A1 (en) * 2001-03-26 2006-10-26 Samuel Zalipsky Liposome composition for improved intracellular delivery of a therapeutic agent
US20050037075A1 (en) * 2003-06-06 2005-02-17 Farokhzad Omid C. Targeted delivery of controlled release polymer systems
US20090181398A1 (en) * 2005-04-28 2009-07-16 Christina Bauer Nanoparticle conjugates
US20100233085A1 (en) 2009-03-10 2010-09-16 Korea Institute Of Science And Technology Ionic complex nanoparticles for detecting heparanase activities and method for preparing the same
US20130039848A1 (en) * 2009-07-02 2013-02-14 Cornell University Fluorescent silica-based nanoparticles
US20120252140A1 (en) * 2009-12-25 2012-10-04 Konica Minolta Medical & Graphic, Inc. Fluorescent substance-containing silica nanoparticles and biosubstance labeling agent
US20140079774A1 (en) 2011-04-28 2014-03-20 Stc.Unm Porous nanoparticle-supported lipid bilayers (protocells) for targeted delivery and methods of using same
US20130337066A1 (en) 2011-06-02 2013-12-19 The Regents Of The University Of California Membrane Encapsulated Nanoparticles and Method of Use

Non-Patent Citations (15)

* Cited by examiner, † Cited by third party
Title
Ahn, B., et al. J. Mater. Chem. B (2013), 1; 2829-2836. *
Banditelli, G., et al. Inorganica Chimica Acta (2002), 330; 72-81. *
Cao, P. et al. (May 2016). "Stem Cell Nanoparticle Constructs for Targeted Ovarian Cancer Therapy," Molecular Therapy 24(Supplement 1):Abstract 209; S81.
Chen, F., et al. J. Nucl. Med. (2014), 55; Suppl. 1; 547. *
Colilla, M., et al. Biomater. Sci. (2013), 1; 114-134. *
Della Rocca, J. et al. (Oct. 24, 2011, e-published Sep. 14, 2011). "Polysilsesquioxane nanoparticles for targeted platin-based cancer chemotherapy by triggered release," Angew Chem Int Ed Engl 50(44):10330-10334.
Gilchrist, M. et al. (2013). "Harnessing neural stem cell tumor tropism for targeted nanoparticle delivery: Potential for ovarian cancer therapy," AACR Poster Presentation, 1 page.
He, Q., et al. Biomaterials (2010), 31; 1085-1092. *
International Search Report dated Mar. 14, 2017, for PCT Application No. PCT/US2016/068978, filed Dec. 28, 2016, 3 pages.
Jokerst, J., et al. Nanomedicine (2011), 6(4); 715-728. *
Mooney, R. et al. (Dec. 23, 2014, e-published Nov. 17, 2014). "Neural stem cell-mediated intratumoral delivery of gold nanorods improves photothermal therapy," ACS Nano 8(12):12450-12460.
Mooney, R. et al. (Feb. 2014). "Neural stem cells improve intracranial nanoparticle retention and tumor-selective distribution," Future Oncol 10(3):401-415.
Mooney, R. et al. (Oct. 10, 2014, e-published Jun. 18, 2014). "Conjugation of pH-responsive nanoparticles to neural stem cells improves intratumoral therapy," Journal of Controlled Release 191:82-89.
Stephan, M. T., et al. Nano Today (2011), 6; 309-325. *
Written Opinion dated Mar. 14, 2017, for PCT Application No. PCT/US2016/068978, filed Dec. 28, 2016, 7 pages.

Also Published As

Publication number Publication date
WO2017117275A1 (fr) 2017-07-06
US20190022246A1 (en) 2019-01-24

Similar Documents

Publication Publication Date Title
US11554178B2 (en) Compositions and methods of modulating macrophage activity
US20220016267A1 (en) Nanoparticles for cancer detection
US11730736B2 (en) Anticancer agents
US20140243357A1 (en) Substituted pyrazolo[3,4-d]pyrimidines and uses thereof
US11304950B2 (en) Methods for treating testicular and ovarian adrenal rest tumors
US10392412B2 (en) Platinum anticancer agents
US20220274964A1 (en) 5-bromo-indirubins
US9795691B2 (en) Chemically-linked nanoparticles
US11696959B2 (en) Nanoparticle-cell construct with platinum anti-cancer agent
US11191745B2 (en) Silica nanoparticle with an insoluble drug
US20220411396A1 (en) Trioxolane agents
US11213510B2 (en) Thioindirubins
US20230114304A1 (en) Depalmitoylating compositions and the use thereof
US10512630B2 (en) Compositions and methods for treating cancer

Legal Events

Date Code Title Description
FEPP Fee payment procedure

Free format text: ENTITY STATUS SET TO UNDISCOUNTED (ORIGINAL EVENT CODE: BIG.); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY

FEPP Fee payment procedure

Free format text: ENTITY STATUS SET TO SMALL (ORIGINAL EVENT CODE: SMAL); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY

STPP Information on status: patent application and granting procedure in general

Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION

AS Assignment

Owner name: CITY OF HOPE, CALIFORNIA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:CAO, PENGPENG;BERLIN, JACOB;ABOODY, KAREN;AND OTHERS;SIGNING DATES FROM 20160331 TO 20160421;REEL/FRAME:049852/0875

Owner name: CITY OF HOPE, CALIFORNIA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:ABIDI, WAFA;REEL/FRAME:049853/0043

Effective date: 20180605

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER

STPP Information on status: patent application and granting procedure in general

Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER

STPP Information on status: patent application and granting procedure in general

Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: FINAL REJECTION COUNTED, NOT YET MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: FINAL REJECTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION

STCF Information on status: patent grant

Free format text: PATENTED CASE